ORIGINAL_ARTICLE
Saffron (Crocus sativus) petal as a new pharmacological target: a review
Saffron petal is the main by-product of saffron processing which produced at high level but it is not applied and thrown out. Saffron petal is containing of several compounds such as mineral agents, anthocyanins, flavonoids, glycosides, alkaloids and kaempferol. As saffron petal is cheaper and produces in large amounts compared to saffron stigma, so, it can be considered as an appropriate source for different purposes. In this review different pharmacological properties of saffron petal such as antibacterial, antispasmodic, immunomodulatory, antitussive, antidepressant, antinociceptive, hepatoprotective, renoprotective, antihypertensive, antidiabetic and antioxidant activity have been introduced. According to these properties, saffron petal can be used as an alternative or supplementary medicine in some diseases.
https://ijbms.mums.ac.ir/article_11575_428711f38a876a4938d2cfa7cb0797c5.pdf
2018-11-01
1091
1099
10.22038/ijbms.2018.31243.7529
Crocus sativus
Saffron petal
Kaempferol
metabolic syndrome
Antidepressant
Hepatoprotective
Azar
Hosseini
hoseiniaz@mums.ac.ir
1
Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad Iran
AUTHOR
Bibi Marjan
Razavi
razavimr@mums.ac.ir
2
Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Hossein
Hosseinzadeh
hosseinzadehh@mums.ac.ir
3
Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Fernández JA. Biology, biotechnology and biomedicine of saffron. Recent Res Dev Plant Sci 2004; 2: 127-159.
1
2. Rios J, Recio M, Giner R, Manez S. An update review of saffron and its active constituents. Phytother Res 1996;10:189-193.
2
3. Schmidt M, Betti G, Hensel A. Saffron in phytotherapy: pharmacology and clinical uses. Wien Med Wochenschr 2007;157:315-319.
3
4. Hosseinzadeh H, Nassiri‐Asl M. Avicenna’s (Ibn Sina) the canon of medicine and saffron (Crocus sativus): a review. Phytother Res 2013;27:475-83.
4
5. Mollazadeh H, Emami SA, Hosseinzadeh H. Razi’s Al-Hawi and saffron (Crocus sativus): a review. Iran J Basic Med Sci 2015;18:1153-1166.
5
6. Khazdair MR, Boskabady MH, Hosseini M, Rezaee R, Tsatsakis AM. The effects of Crocus sativus (saffron) and its constituents on nervous system: A review. Avicenna J Phytomed 2015;5:376-391.
6
7. Hosseinzadeh H, Ghenaati J. Evaluation of the antitussive effect of stigma and petals of saffron (Crocus sativus) and its components, safranal and crocin in guinea pigs. Fitoterapia 2006;77:446-448.
7
8. Asdaq SMB, Inamdar MN. Potential of Crocus sativus (saffron) and its constituent, crocin, as hypolipidemic and antioxidant in rats. Appl Biochem Biotechnol 2010;162:358-372.
8
9. Hosseinzadeh H, Khosravan V. Anti-convulsant effects of aqueous and ethanolic extracts of Crocus sativus L stigma in mice. Arch Iran Med 2002; 5:44-47.
9
10. Hosseinzadeh H, Younesi HM. Antinociceptive and anti-inflammatory effects of Crocus sativus L. stigma and petal extracts in mice. BMC Pharmacol 2002; 15: 2-7.
10
11. Hosseinzadeh H, Karimi G, Niapoor M, editors. Antidepressant effect of Crocus sativus L. stigma extracts and their constituents, crocin and safranal, in mice.J Med Plants 2004; 3:48-58
11
12. Hosseinzadeh H, Noraei NB. Anxiolytic and hypnotic effect of Crocus sativus aqueous extract and its constituents, crocin and safranal, in mice. Phytother Res 2009;23:768-774.
12
13. Imenshahidi M, Hosseinzadeh H, Javadpour Y. Hypotensive effect of aqueous saffron extract (Crocus sativus L.) and its constituents, safranal and crocin, in normotensive and hypertensive rats. Phytother Res 2010;24:990-994.
13
14. Abdullaev F, Espinosa-Aguirre J. Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials. Cancer Detect Prev 2004;28:426-432.
14
15. Hosseinzadeh H, Sadeghnia HR, Ziaee T, Danaee A. Protective effect of aqueous saffron extract (Crocus sativus L.) and crocin, its active constituent, on renal ischemia-reperfusion-induced oxidative damage in rats. J Pharm Pharm Sci 2005;8:387-393.
15
16. Hosseinzadeh H, Shamsaie F, Mehri S. Antioxidant activity of aqueous and ethanolic extracts of Crocus sativus L. stigma and its bioactive constituents, crocin and safranal. Pharmacogn Mag 2009;5:419-424.
16
17. Fahim NK, Janati SF, Feizy J. Chemical composition of agriproduct saffron (Crocus sativus L.) petals and its considerations as animal feed. GIAD J Food 2012;37:197-201.
17
18. Hadizadeh F, Khalili N, Hosseinzadeh H, Khair-Aldine R. Kaempferol from saffron petals. Iran J Pharm Res 2003; 2: 251-252.
18
19. eka K, Ruparelia KC, Continenza MA, Stagos D, Vegliò F, Arroo RR. Petals of Crocus sativus L. as a potential source of the antioxidants crocin and kaempferol. Fitoterapia 2015;107:128-134.
19
20. Khazaei KM, Jafari S, Ghorbani M, Kakhki AH, Sarfarazi M. Optimization of anthocyanin extraction from saffron petals with response surface methodology. Food Anal Methods 2016;9:1993-2001.
20
21. Goli SAH, Mokhtari F, Rahimmalek M. Phenolic compounds and antioxidant activity from saffron (Crocus sativus L.) petal. J Agric Sci 2012;4:175-181.
21
22. Termentzi A, Kokkalou E. LC-DAD-MS (ESI+) analysis and antioxidant capacity of crocus sativus petal extracts. Planta Med 2008;74:573-581.
22
23. Righi V, Parenti F, Tugnoli V, Schenetti L, Mucci A. Crocus sativus petals: waste or valuable resource? The answer of high-resolution and High-resolution magic angle spinning nuclear magnetic resonance. J Agric Food Chem 2015;63:8439-8444.
23
24. Li C-Y, Lee E-J, Wu T-S. Antityrosinase Principles and Constituents of the Petals of Crocus
24
sativus. J Nat Prod 2004;67:437-440.
25
25. Hosseini D, Shariatmadar S. Identification of anthocyanins of Crocus sativus petals. Iran Inst Sci Technol Rep, Khorasan Center 1994.
26
26. Astarei AR, Eskandari-Torbaghan M, Abbasi-Ali Kamar R, editors. Effect of saffron (crocus sativus L.) petals on germination and primary growth of cotton (gossypium hirsutum L.). II Int Symp Saffron Biol Technol 2006; 739: 87-91.
27
27. Mortazavi S, Kamali MM, Safi S, Salehi R. Saffron petals, a by-product for dyeing of wool fibers. Prog Color Colorants Coat 201; 5: 75-84.
28
28. Johler S, Tichaczek-Dischinger PS, Rau J, Sihto HM, Lehner A, Adam M. Outbreak of Staphylococcal food poisoning due to SEA-producing Staphylococcus aureus. Food Pathog Dis 2013;10:777-781.
29
29. Madhumitha G, Saral AM. Preliminary phytochemical analysis, antibacterial, antifungal and anticandidal activities of successive extracts of Crossandra infundibuliformis. Asian Pac J Trop Med 2011;4:192-195.
30
30. Forouzanfar F, Bazzaz BSF, Hosseinzadeh H. Black cumin (Nigella sativa) and its constituent (thymoquinone): a review on antimicrobial effects. Iran J Basic Med Sci 2014;17:929-938.
31
31. Asgarpanah J, Darabi-Mahboub E, Mahboubi A, Mehrab R, Hakemivala M. In-Vitro Evaluation of Crocus Sativus L. Petals and Stamens as Natural Antibacterial Agents Against Food-Borne Bacterial Strains. Iran J Pharm Sci 2013;9:69-82.
32
32. Fatehi M, Rashidabady T, Fatehi-Hassanabad Z. Effects of Crocus sativus petals’ extract on rat blood pressure and on responses induced by electrical field stimulation in the rat isolated vas deferens and guinea-pig ileum. J Ethnopharmacol 2003;84:199-203.
33
33. Patwardhan B, Gautam M. Botanical immunodrugs: scope and opportunities. Drug Discov Today 2005;10:495-502.
34
34. Plaeger SF. Clinical immunology and traditional herbal medicines. Clin Diagn Lab Immunol 2003;10:337-338.
35
35. Zeinali M, Rezaee SA, Hosseinzadeh H. An overview on immunoregulatory and anti-inflammatory properties of chrysin and flavonoids substances. Biomed Pharmacother 2017;92:998-1009.
36
36. Babaei A, Arshami J, Haghparast A, Mesgaran MD. Effects of saffron (Crocus sativus) petal ethanolic extract on hematology, antibody response, and spleen histology in rats. Avicenna J Phytomed 2014;4:103-109.
37
37. Agha‐Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara A, et al. Crocus sativus L.(saffron) in the treatment of premenstrual syndrome: a double‐blind, randomised and placebo‐controlled trial. BJOG: An Int J Obst Gynaecol 2008;115:515-519.
38
38. Bikomo E, Ebuehi O, Magbagbeola O. Antidepressant Activity of Ethanol Leaf Extract of Annona muricata L., in Sprague-Dawley Rats. Am J Biochem 2017;7:1-5.
39
39. Karimi GR, Hosseinzadeh H, Khaleghpanah P. Study of antidepressant effect of aqueous and ethanolic extract of Crocus sativus in mice. Irn J Basic Med Sci 2001; 4: 11-15.
40
40. Tabeshpour J, Sobhani F, Sadjadi SA, Hosseinzadeh H, Mohajeri SA, Rajabi O, et al. A double-blind, randomized, placebo-controlled trial of saffron stigma (Crocus sativus L.) in mothers suffering from mild-to-moderate postpartum depression. Phytomed 2017;36:145-152.
41
41. Hassani FV, Naseri V, Razavi BM, Mehri S, Abnous K, Hosseinzadeh H. Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus. Daru J Pharm Sci 2014;22:16.
42
42. Ghasemi T, Abnous K, Vahdati F, Mehri S, Razavi B, Hosseinzadeh H. Antidepressant effect of Crocus sativus aqueous extract and its effect on CREB, BDNF, and VGF transcript and protein levels in rat hippocampus. Drug Res 2015;65:337-343.
43
43. Moshiri E, Basti AA, Noorbala A-A, Jamshidi A-H, Abbasi SH, Akhondzadeh S. Crocus sativus L.(petal) in the treatment of mild-to-moderate depression: A double-blind, randomized and placebo-controlled trial. Phytomed 2006;13:607-611.
44
44. Basti AA, Moshiri E, Noorbala A-A, Jamshidi A-H, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuro-Psychopharmacol Biol Psychiatry 2007;31:439-442.
45
45. Hosseinzadeh H, Motamedshariaty V, Hadizadeh F. Antidepressant effect of kaempferol, a constituent of saffron (Crocus sativus) petal, in mice and rats. Pharmacologyonline 2007;2:367-370.
46
46. Gholamnezhad Z, Koushyar H, Byrami G, Boskabady MH. The extract of Crocus sativus and its constituent safranal, affect serum levels of endothelin and total protein in sensitized guinea pigs. Iran J Basic Med Sci 2013;16:1022-1026.
47
47. Boskabady MH, Farkhondeh T. Antiinflammatory, antioxidant, and immunomodulatory effects of Crocus sativus L. and its main constituents. Phytother Res 2016;30:1072-1094.
48
48. Boskabady MH, Rahbardar MG, Jafari Z. The effect of safranal on histamine (H1) receptors of guinea pig tracheal chains. Fitoterapia 2011;82:162-167.
49
49. Manibusan MK, Odin M, Eastmond DA. Postulated carbon tetrachloride mode of action: a review. J Environ Sci Health Part C 2007;25:185-209.
50
50. Kamalakkannan N, Rukkumani R, Varma PS, Viswanathan P, Rajasekharan KN, Menon VP. Comparative Effects of Curcumin and an Analogue of Curcumin in Carbon Tetrachloride‐Induced Hepatotoxicity in Rats. Basic Clin Pharmacol Toxicol 2005;97:15-21.
51
51. Iranshahi M, Khoshangosht M, Mohammadkhani Z, Karimi G. Protective effects of aqueous and ethanolic extracts of saffron stigma and petal on liver toxicity induced by carbon tetrachloride in mice. Pharmacologyonline 2011;1:203-212.
52
52. Bunchorntavakul C, Reddy KR. Acetaminophen-related hepatotoxicity. Clin Liver Dis 2013;17:587-607.
53
53. Tan SC, New LS, Chan EC. Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine. Toxicol Let 2008;180:174-181.
54
54. Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol 2010; 196: 369-405.
55
55. Omidi A, Riahinia N, Torbati MBM, Behdani M-A. Hepatoprotective effect of Crocus sativus (saffron) petals extract against acetaminophen toxicity in male Wistar rats. Avicenna J Phytomed 2014;4:330-336.
56
56. Nakanuma Y. Non‐neoplastic nodular lesions in the liver. Pathol Int 1995;45:703-714.
57
57. Omidi A, Torabi Z, Hassanpoorfard M, Zardast M. Evaluation of protective effect of hydroalcoholic extract of Crocus sativus petals on preventing of gentamicin induced peliosis hepatis and hepatic telangiectasis in rats. J Birjand Univ Med Sci 2013;19:455-462.
58
58. Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother 1993;27:438-4341.
59
59. Robbins ME, Zhao W, Davis CS, Toyokuni S, Bonsib SM. Radiation-induced kidney injury: a role for chronic oxidative stress? Micron 2002;33:133-141.
60
60. Mohajeri Dariush DY. Protective effects of Crocus sativus petal against cisplatin-induced hepatotoxicity in rats. Med Sci J Islamic Azad Univ 2011;21:251-261.
61
61. Omidi A, Riahinia N, Torbati MBM, Behdani MA. Evaluation of protective effect of hydroalcoholic extract of saffron petals in prevention of acetaminophen-induced renal damages in rats. Vet Sci Dev 2015;5: 68-71.
62
62. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48-60.
63
63. Tousian HS, Razavi BM, Hosseinzadeh H. Review of Garcinia mangostana and its xanthones in metabolic syndrome and related complications. Phytother Res 2017; 31: 1173-1182.
64
64. Tabeshpour J, Imenshahidi M, Hosseinzadeh H. A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome. Iran J Basic Med Sci 2017;20:557-568.
65
65. Razavi BM, Lookian F, Hosseinzadeh H. Protective effects of green tea on olanzapine-induced-metabolic syndrome in rats. Biomed Pharmacother 2017;92:726-731.
66
66. Tabeshpour J, Razavi BM, Hosseinzadeh H. Effects of Avocado (Persea americana) on metabolic syndrome: a comprehensive systematic review. Phytother Res 2017; 31: 819-837.
67
67. Mollazadeh H, Hosseinzadeh H. Cinnamon effects on metabolic syndrome: a review based on its mechanisms. Iran J Basic Med Sci 2016;19:1258-1270.
68
68. Hassani FV, Shirani K, Hosseinzadeh H. Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: a review. Naunyn-Schmiedeberg’s Arch Pharmacol 2016;389:931-49.
69
69. Akaberi M, Hosseinzadeh H. Grapes (Vitis vinifera) as a potential candidate for the therapy of the metabolic syndrome. Phytother Res 2016;30:540-556.
70
70. Hosseini A, Hosseinzadeh H. A review on the effects of Allium sativum (Garlic) in metabolic syndrome. J Endocrin Invest 2015;38:1147-1157.
71
71. Razavi B, Hosseinzadeh H. A review of the effects of Nigella sativa L. and its constituent, thymoquinone, in metabolic syndrome. J Endocrinol Invest 2014;37:1031-1040.
72
72. Razavi BM, Hosseinzadeh H. Saffron: a promising natural medicine in the treatment of metabolic syndrome. J Sci Food Agric 2017;97:1679-1685.
73
73. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-2600.
74
74. Hoshyar R, Hosseinian M, Naghandar MR, Hemmati M, Zarban A, Amini Z, et al. Anti-dyslipidemic properties of Saffron: Reduction in the associated risks of atherosclerosis and insulin resistance. Iran Red Cres Med J 2016;18: e36266.
75
75. Lenzen S. The mechanisms of alloxan-and streptozotocin-induced diabetes. Diabetol 2008;51:216-226.
76
76. Zarez et al adeh M, Vazifeshenas-Darmiyan K, Afshar M, Valavi M, Serki E, Hosseini M. Effects of Extract of Crocus sativus Petal on Renal Function in Diabetic Rats. J Mazandaran Univ Med Sci 2017;27:11-24.
77
77. Halliwell B. Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept. Nutr Rev 1999;57:104-113.
78
78. Ardalan T, Ardalan P, Heravi M. Kinetic study of free radicals scavenging by saffron petal extracts. J Chem Health Risks. 2012;2: 29-36.
79
79. Hosseinzadeh H, Behravan J, Ramezani M, Ajgan K. Anti-tumor and cytotoxic evaluation of Crocus sativus L. stigma and petal extracts using brine shrimp and potato disc assays. J Med Plants 2005;3:59-65.
80
80. Karimi G, Tabibi N, Hosseinzadeh H, Shirzad F. Sub-acute toxicity of saffron (Crocus sativus L.) stigma and petal in rats. J Med Plants 2004;12:32-39.
81
ORIGINAL_ARTICLE
Formation of therapeutic phage cocktail and endolysin to highly multi-drug resistant Acinetobacter baumannii: in vitro and in vivo study
Objective(s): Phage therapy is a potential alternative treatment for infections caused by Acinetobacter baumannii, a significant nosocomial pathogen, which has evolved resistance to almost all conventional antimicrobial drugs in poor hygiene and conflicts areas such as Iraq. Materials and Methods: Bacteriophages were isolated to highly resistant isolates of A. baumannii to form therapeutic phage cocktail, and to extract and evaluate native endolysin activity. Bacterial samples were collected in Al-Imamein Al-kadhimein Medical City Hospital. Phages were isolated from different regions in Baghdad city including (soil, sewage, irrigation channels). Phage endolysin was extracted from highly lytic phages that produced halo-like appearance around inhibition zone. Results: Up to 23 isolates of extensive- and pan- drug resistant (XDR, PDR) A. baumannii were isolated from patients with various infections, and 136 lytic phages specific to A. baumannii were isolated. Each bacterial isolate was sensitive to at least one lytic phage. Accordingly, a phage cocktail was formulated which remarkably minimized bacterial resistance to lysis by phages when compared to individual lytic phages. And, the phage cocktail succeeded in treating and saving life of all bacteremic mice with A. baumannii versus the non-treated group. In addition, the endolysin native activity to A. baumannii was evaluated in this study; endolysin revealed a potent antibacterial activity (> 1 log) reduction of bacterial density in just one hour of endolysin treatment. Conclusion: The phage therapy assessed in this study showed an ability to efficiently solve the problems of “superbug” bacteria by lysing effectively most XDR, PDR bacteria in vitro and in vivo. And, phage cocktail was shown to be superior over single-phage preparations in treating A. baumannii with much less resistance rate to therapeutic phages. Furthermore, intrinsic activity of native endolysin revealed promising results to tackling superbug pathogens.
https://ijbms.mums.ac.ir/article_11603_71ca2a6cfc1d8676dc03bf3027c5ecff.pdf
2018-11-01
1100
1108
10.22038/ijbms.2018.27307.6665
Acinetobacter baumannii
Bacteriophages
Drug resistance
Endolysin
Phage therapy
Hayder
Nsaif Jasim
haider.nasef@gmail.com
1
College of Medicine, AL-Nahrain University, Medical Microbiology Department, Baghdad, Iraq
LEAD_AUTHOR
Rand
Riadh Hafidh
ranria77@yahoo.com
2
College of Medicine, Baghdad University, Department of Microbiology, Baghdad, Iraq
AUTHOR
Ahmed
Sahib Abdulamir
ahmsah73@yahoo.com
3
College of Medicine, AL-Nahrain University, Medical Microbiology Department, Baghdad, Iraq
AUTHOR
1. Cantas L, Shah S, Cavaco L, Manaia C, Walsh F, Popowska M, et al. A brief multi-disciplinary review on antimicrobial resistance in medicine and its linkage to the global environmental microbiota. Front Microbiol 2013; 4:96-110.
1
2. World Health Organization. Antimicrobial resistance: global report on surveillance. World Health Organization 2014.
2
3. Murray CK, Yun HC, Griffith ME, Thompson B, Crouch HK, Monson LS, et al. Recovery of multidrug-resistant bacteria from combat personnel evacuated from Iraq and Afghanistan at a single military treatment facility. Mil Med 2009; 174:598-604.
3
4. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:510-526.
4
5. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. Review of antimicrobial resistance. London: HM Government and Wellcome trust 2016. There is no corresponding record for this reference. 2016.
5
6. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011; 1:66-85.
6
7. Hendrix RW, Smith MC, Burns RN, Ford ME, Hatfull GF. Evolutionary relationships among diverse bacteriophages and prophages: all the world’sa phage. Proc Natl Acad Sci U S A 1999; 96:2192-2197.
7
8. Clokie MR, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage 2011; 1:31-45.
8
9. Flores CO, Meyer JR, Valverde S, Farr L, Weitz JS. Statistical structure of host–phage interactions. Proc Natl Acad Sci U S A 2011; 108:E288-E297.
9
10. Örmälä AM, Jalasvuori M. Phage therapy: should bacterial resistance to phages be a concern, even in the long run?. Bacteriophage 2013; 3:24219-24222.
10
11. Mattila S, Ruotsalainen P, Jalasvuori M. On-demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy. Front Microbiol 2015; 6:1271-1278.
11
12. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45:649-659.
12
13. Chan BK, Abedon ST. Phage therapy pharmacology: phage cocktails. Adv Appl Microbiol 2012; 78:1-23.
13
14. Falagas ME, Vardakas KZ, Kapaskelis A, Triarides NA, Roussos NS. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents 2015; 45:455-460.
14
15. Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiol 2012; 7:1147-1171.
15
16. Briers Y, Walmagh M, Lavigne R. Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J Appl Microbiol 2011; 110: 778-785.
16
17. Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, et al. Engineered endolysin-based “Artilysins” to combat multidrug-resistant Gram-negative pathogens. MBio 2014; 5:e01379-01314.
17
18. Merril CR, Scholl D, Adhya SL. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2003; 2:489-497.
18
19. WHO (World Health Organization). 2003. Basic laboratory procedures in clinical bacteriology .2nd ed. Geneva, Switzerland. pp: 103-121.
19
20. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing: Twenty-fourth informational supplement, M100-S24. Clinical and Laboratory Standards Institute (CLSI) 2014; 34.
20
21. Jassim SA, Abdualamir AS and Abu baker F. Methods for bacteriophage design in "international application published under the patent cooperation (PCT)" (W.I.P. organization, ed.) 2010; Vol.WO2010064044 A1.
21
22. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect immun 2002; 70:204-210.
22
23. Simmons M, Donovan DM, Siragusa GR, Seal BS. Recombinant expression of two bacteriophage proteins that lyse Clostridium perfringens and share identical sequences in the C-terminal cell wall binding domain of the molecules but are dissimilar in their N-terminal active domains. J Agric Food Chem 2010; 58:10330-10337.
23
24. Mshachal MA, Abdulrahman TR, Khudair MS, Hassan JS. Molecular detection of multidrug resistance Acinetobacter baumannii from different clinical samples. Iraqi J Med Sci 2017; 15:314-323.
24
25. Al Marjani M, Al-Ammar M, Kadhem E. Occurrence of ESBL and MBL genes in Pseudomonas aeruginosa and Acinetobacter baumannii isolated from Baghdad, Iraq. Int J Cur Res 2013; 5:2482-2486.
25
26. Qureshi ZA, Hittle LE, O'hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 2015; 60:1295-1303.
26
27. Pelletier MR, Casella LG, Jones JW, Adams MD, Zurawski DV, Hazlett KR, et al. Unique structural modifications are present in the LPS from colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2013; 51:4831-4840.
27
28. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother 2011; 55:3743-3751.
28
29. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004; 38:1449-1459.
29
30. Rodríguez-Martínez JM, Nordmann P, Ronco E, Poirel L. Extended-spectrum cephalosporinase in Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54:3484-3488.
30
31. Bragg R, van der Westhuizen W, Lee JY, Coetsee E, Boucher C. Bacteriophages as potential treatment option for antibiotic resistant bacteria. Adv Exp Med Biol 2014; 807:97-110.
31
32. Kusradze I, Karumidze N, Rigvava S, Dvalidze T, Katsitadze M, Amiranashvili I, et al. Characterization and testing the efficiency of Acinetobacter baumannii phage vB-GEC_Ab-M-G7 as an antibacterial agent. Front Microbiol 2016; 7:1590-1597.
32
33. Regeimbal JM, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, et al. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob Agents Chemother 2016; 60:5806-5816.
33
34. Merabishvili M, Vandenheuvel D, Kropinski AM, Mast J, De Vos D, Verbeken G, et al. Characterization of newly isolated lytic bacteriophages active against Acinetobacter baumannii. PLoS ONE 2014; 9:104853-104864.
34
35. Łobocka M, Hejnowicz MS, Gagała U, Weber-Dabrowska B, Wegrzyn G, Dadlez M. The first step to bacteriophage therapy—How to choose the correct phage. Phage Therapy: Current Research and Applications; Borysowski, J, Miedzybrodzki, R, Górski, A, Eds. 2014:23-69.
35
36. Jassim S, Abdulamir A, Abu Bakar F. Phage-based limulus amoebocyte lysate assay for rapid detection of bacteria. WO2011/098820A1. 2011.
36
37. Kelly D, McAuliffe O, O’Mahony J, Coffey A. Development of a broad-host-range phage cocktail for biocontrol. Bioeng bugs 2011; 2:31-37.
37
38. Benjamin K Chan, Stephen T Abedon, Catherine Loc-Carrillo Future Microbiol 2013; 8:769-783.
38
39. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538-582.
39
40. Lai MJ, Lin NT, Hu A, Soo PC, Chen LK, Chen LH, et al. Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin (LysAB2) against both Gram-positive and Gram-negative bacteria. Appl Microbiol Biotechnol 2011; 90:529-539.
40
41. Briers Y, Volckaert G, Cornelissen A, Lagaert S, Michiels CW, Hertveldt K, et al. Muralytic activity and modular structure of the endolysins of Pseudomonas aeruginosa bacteriophages φKZ and EL. Mol Microbiol 2007; 65:1334-1344.
41
42. Miroshnikov K, Faizullina N, Sykilinda N, Mesyanzhinov V. Properties of the endolytic transglycosylase encoded by gene 144 of Pseudomonas aeruginosa bacteriophage phiKZ. Biochem (Mosc) 2006; 71:300-305.
42
43. Paradis-Bleau C, Cloutier I, Lemieux L, Sanschagrin F, Laroche J, Auger M, et al. Peptidoglycan lytic activity of the Pseudomonas aeruginosa phage φKZ gp144 lytic transglycosylase. FEMS Microbiol Lett 2007; 266:201-209.
43
44. Junn HJ, Youn J, Suh KH, Lee SS. Cloning and expression of Klebsiella phage K11 lysozyme gene. Protein Expr Purif 2005; 42:78-84.
44
45. Mikoulinskaia GV, Odinokova IV, Zimin AA, Lysanskaya VY, Feofanov SA, Stepnaya OA. Identification and characterization of the metal ion‐dependent l‐alanoyl‐d‐glutamate peptidase encoded by bacteriophage T5. FEBS J 2009; 276:7329-7342.
45
46. Schmelcher M, Shabarova T, Eugster MR, Eichenseher F, Tchang VS, Banz M, et al. Rapid multiplex detection and differentiation of Listeria cells by use of fluorescent phage endolysin cell wall binding domains. Appl Environ Microbiol 2010; 76:5745-5756.
46
47. Loessner MJ, Kramer K, Ebel F, Scherer S. C‐terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high‐affinity binding to bacterial cell wall carbohydrates. Mol Microbiol 2002; 44:335-349.
47
48. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, et al. Novel phage lysin capable of killing the multidrug-resistant Gram negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother 2015; 59:1983-1991.
48
49. Hibbing ME, Fuqua C, Parsek MR, Peterson SB. Bacterial competition: surviving and thriving in the microbial jungle. Nat Rev Microbiol 2010; 8:15-25.
49
50. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
50
51. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 2010; 201:1096-1104.
51
52. Pires DP, Vilas Boas D, Sillankorva S, Azeredo J. Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 2015; 89:7449-7456.
52
53. McCallin S, Alam Sarker S, Barretto C, Sultana S, Berger B, Huq S, et al. Safety analysis of a Russian phage cocktail: from metagenomics analysis to oral application in healthy human subjects. Virology 2013; 443:187-196.
53
54. Reyes A, Semenkovich NP, Whiteson K, Rohwer F, Gordon JI. Going viral: next-generation sequencing applied to phage populations in the human gut. Nat Rev Microbiol 2012; 10:607-617.
54
55. Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol Lett 2007; 29:995-1003.
55
56. Merril CR, Scholl D, Adhya S. Phage Therapy. In Calendar R, editor. The Bacteriophages. New York: Oxford University Press; 2006. P 725-741.
56
ORIGINAL_ARTICLE
Effects of assisted oocyte activation with calcium- ionophore and strontium chloride on in vitro ICSI outcomes
Objective(s): Failed fertilization after intra-cytoplasmic sperm injection (ICSI) is mainly attributed to failed oocyte activation and can be overcome by artificial oocyte activation (AOA). The present study aims to compare in vitro outcomes of ICSI following two different assisted oocyte activation chemical procedures (SrCl2 and Ionomycin) in sibling oocytes of ICSI candidates.Materials and Methods: From March 2015 until February 2016, 105 infertile men with 99–100% abnormal sperm morphology, irrespective of sperm motility, concentration, or origin (semen or testicular) were included in this study. Out of these, 66 couples accepted to be included in the study group (Ionomycin/ SrCl2) and 39 couples requested routine AOA procedure (Ionomycin) as external control group. Primary outcomes of this study (fertilization, embryo quality, and post-implantation development) were compared between these groups.Results: Significantly higher oocyte activation (67.90±3.6% vs. 51.16±3.6%, P=0.004) and fertilization (65.23±3.63% vs. 49.65±3.63%, P=0.008) rates were observed in sibling oocytes treated with Ionomycin in comparison to the SrCl2 sibling group. Percentage of top quality embryos was insignificantly higher in SrCl2 groups compared to the Ionomycin group (29.90±4.27 vs. 20.65±4.05%, P=0.26).Conclusion: Ionomycin may be superior to SrCl2 for inducing oocyte activation. However, SrCl2 may be a more efficient means to support the development of better quality embryos following ICSI.
https://ijbms.mums.ac.ir/article_11606_633a0053b1ee49557b7e6c52d3538732.pdf
2018-11-01
1109
1117
10.22038/ijbms.2018.30422.7331
Fertilization
Implantation
Ionomycin
pregnancy
Strontium
Marziyeh
Norozi-Hafshejani
marziyehn21@gmail.com
1
Department of Reproductive Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
AUTHOR
Marziyeh
Tavalaee
tavalaee.royan@gmail.com
2
Department of Reproductive Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
AUTHOR
Leila
Azadi
azadi_2021@yahoo.com
3
Department of Reproductive Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
AUTHOR
Mehrnoosh
Bahadorani
m.bahadorani87@gmail.com
4
Department of Biology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
AUTHOR
Mohamad Hosein
Nasr Esfahani
mh_nasr@med.mui.ac.ir
5
Department of Reproductive Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
LEAD_AUTHOR
1. Neri QV, Lee B, Rosenwaks Z, Machaca K, Palermo GD. Understanding fertilization through intracytoplasmic sperm injection (ICSI). Cell Calcium 2014; 55:24-37.
1
2. Palermo GD, Neri QV, Takeuchi T, Rosenwaks Z. ICSI: where we have been and where we are going. Semin Reprod Med 2009; 27:191-201.
2
3. Mahutte NG, Arici A. Failed fertilization: is it predictable? Curr Opin Obstet Gynecol 2003; 15:211-218.
3
4. Javed M, Esfandiari N, Casper RF. Failed fertilization after clinical intracytoplasmic sperm injection. Reprod Biomed Online 2010; 20:56-67.
4
5. Swain JE, Pool TB. ART failure: oocyte contributions to unsuccessful fertilization. Hum Reprod Update 2008; 14:431-1446.
5
6. Amdani SN, Yeste M, Jones C, Coward K. Phospholipase C zeta (PLCζ) and male infertility: Clinical update and topical developments. Adv Biol Regul 2016; 61:58-67.
6
7. Kashir J, Nomikos M, Swann K, Lai FA. PLCζ or PAWP: revisiting the putative mammalian sperm factor that triggers egg activation and embryogenesis. Mol Hum Reprod 2015; 21: 383-388.
7
8. Yeste M, Jones C, Amdani SN, Patel S, Coward K. Oocyte activation deficiency: a role for an oocyte contribution? Hum Reprod Update 2016; 22: 23-47.
8
9. Aghajanpour S, Ghaedi K, Salamian A, Deemeh MR, Tavalaee M, Moshtaghian J, et al. Quantitative expression of phospholipase C zeta, as an index to assess fertilization potential of a semen sample. Hum Reprod 2011; 26: 2950-2956.
9
10. Chansel-Debordeaux L, Dandieu S, Bechoua S, Jimenez C. Reproductive outcome in globozoospermic men: update and prospects. Andrology 2015; 3:1022-1034.
10
11. Escoffier J, Yassine S, Lee HC, Martinez G, Delaroche J, Coutton C, et al. Subcellular localization of phospholipase Cζ in human sperm and its absence in DPY19L2-deficient sperm are consistent with its role in oocyte activation. Mol Hum Reprod 2015; 21: 157-168.
11
12. Heytens E, Parrington J, Coward K, Young C, Lambrecht S, Yoon SY, et al. Reduced amounts and abnormal forms of phospholipase C zeta (PLCzeta) in spermatozoa from infertile men. Hum Reprod 2009; 24: 2417-2428.
12
13. Kamali-Dolat Abadi M, Tavalaee M, Shahverdi A, Nasr-Esfahani MH. Evaluation of PLCζ and PAWP expression in globozoospermic individuals. Cell J 2016; 18: 438-445.
13
14. Amdani SN, Jones C, Coward K. Phospholipase C zeta (PLCζ): oocyte activation and clinical links to male factor infertility. Adv Biol Regul 2013; 53: 292-308.
14
15. Tavalaee M, Kiani-Esfahani A, Nasr-Esfahani MH. Relationship between potential sperm factors involved in oocyte activation and sperm DNA fragmentation with intra-cytoplasmic sperm injection clinical outcomes. Cell J 2017; 18: 588-596.
15
16. Vanden Meerschaut F, Nikiforaki D, De Roo C, Lierman S, Qian C, Schmitt-John T, et al. Comparison of pre- and post-implantation development following the application of three artificial activating stimuli in a mouse model with round-headed sperm cells deficient for oocyte activation. Hum Reprod 2013; 28:1190-1198.
16
17. Darabi MR, Shiravi A, Hojati V. The effects of ethanol and strontium on growth and development of two-cell arrested mouse embryos. Int J Fertil Steril 2012; 5:197-202.
17
18. Nasr-Esfahani MH, Tavalaee M, Deemeh MR, Arbabian M, Parrington J. Can assessment of total acrosin activity help predict failed or low fertilization rate ICSI for implementation of artificial oocyte activation? The open andrology journal 2010, 2:19-26.
18
19. Nasr-Esfahani MH, Razavi S, Javdan Z, Tavalaee M. Artificial oocyte activation in severe teratozoospermia undergoing intracytoplasmic sperm injection. Fertil Steril 2008; 90: 2231-2237.
19
20. Vanden Meerschaut F, Nikiforaki D, Heindryckx B, De Sutter P. Assisted oocyte activation following ICSI fertilization failure. Reprod Biomed Online 2014; 28: 560-571.
20
21. Chi HJ, Koo JJ, Song SJ, Lee JY, Chang SS. Successful fertilization and pregnancy after intracytoplasmic sperm injection and oocyte activation with calcium ionophore in a normozoospermic patient with extremely low fertilization rates in intracytoplasmic sperm injection cycles. Fertil Steril 2004; 82: 475-477.
21
22. Deemeh MR, Tavalaee M, Nasr-Esfahani MH. Health of children born through artificial oocyte activation: a pilot study. Reprod Sci 2015; 22: 322-328.
22
23. D’haeseleer E, Vanden Meerschaut F, Bettens K, Luyten A, Gysels H, Thienpont Y, et al. Language development of children born following intracytoplasmic sperm injection (ICSI) combined with assisted oocyte activation (AOA). Int J Lang Commun Disord 2014; 49: 702-709.
23
24. Eldar-Geva T, Brooks B, Margalioth EJ, Zylber-Haran E, Gal M, Silber SJ. Successful pregnancy and delivery after calcium ionophore oocyte activation in a normozoospermic patient with previous repeated failed fertilization after intracytoplasmic sperm injection. Fertil Steril 2003; 79 Suppl 3:1656-8
24
25. Vanden Meerschaut F, D’Haeseleer E, Gysels H, Thienpont Y, Dewitte G, Heindryckx B, et al. Neonatal and neurodevelopmental outcome of children aged 3-10 years born following assisted oocyte activation. Reprod Biomed Online 2014; 28: 54-63.
25
26. Ebner T, Köster M, Shebl O, Moser M, Van der Ven H, Tews G, et al. Application of a ready-to-use calcium ionophore increases rates of fertilization and pregnancy in severe male factor infertility. Fertil Steril 2012; 98:1432-1437.
26
27. Mortimer D. Comparison of the fertilizing ability of human spermatozoa preincubated in calcium- and strontium-containing media. J Exp Zool 1986; 237: 21-4.
27
28. Mortimer D, Curtis EF, Dravland JE. The use of strontium-substituted media for capacitating human spermatozoa: an improved sperm preparation method for the zona-free hamster egg penetration test. Fertil Steril 1986; 46: 97-103.
28
29. Kline D, Kline JT. Repetitive calcium transients and the role of calcium in exocytosis and cell cycle activation in the mouse egg. Dev Biol 1992; 149: 80-89.
29
30. Suganuma R, Walden CM, Butters TD, Platt FM, Dwek RA, Yanagimachi R, et al. Alkylated imino sugars, reversible male infertility-inducing agents, do not affect the genetic integrity of male mouse germ cells during short-term treatment despite induction of sperm deformities. Biol Reprod 2005; 72: 805-813.
30
31. Tesarik J, Mendoza C, Greco E. The activity (calcium oscillator?) responsible for human oocyte activation after injection with round spermatids is associated with spermatid nuclei. Fertil Steril 2000; 74:1245-1247.
31
32. Yanagida K, Morozumi K, Katayose H, Hayashi S, Sato A. Successful pregnancy after ICSI with strontium oocyte activation in low rates of fertilization. Reprod Biomed Online 2006; 13:801-806.
32
33 Borges E Jr, de Almeida Ferreira Braga DP, de Sousa Bonetti TC, Iaconelli A Jr, Franco JG Jr. Artificial oocyte activation with calcium ionophore A23187 in intracytoplasmic sperm injection cycles using surgically retrieved spermatozoa. Fertil Steril 2009; 92:131-136.
33
34. Kang HJ, Lee SH, Park YS, Lim CK, Ko DS, Yang KM, et al. Artificial oocyte activation in intracytoplasmic sperm injection cycles using testicular sperm in human in vitro fertilization. Clin Exp Reprod Med 2015; 42:45-50.
34
35. Mansour R, Fahmy I, Tawab NA, Kamal A, El-Demery Y, Aboulghar M, et al. Electrical activation of oocytes after intracytoplasmic sperm injection: a controlled randomized study. Fertil Steril 2009; 91:133-139.
35
36. Moaz MN, Khattab S, Foutouh IA, Mohsen EA. Chemical activation of oocytes in different types of sperm abnormalities in cases of low or failed fertilization after ICSI: a prospective pilot study. Reprod Biomed Online 2006; 13:791-794.
36
37. World Health Organization. Examination and processing human semen. (5th Ed.), Cambridge University press, WHO, 2010.
37
38. Levron J, Munné S, Willadsen S, Rosenwaks Z, Cohen J. Male and female genomes associated in a single pronucleus in human zygotes. Biol Reprod 1995; 52:653-657.
38
39. Sultan KM, Munné S, Palermo GD, Alikani M, Cohen J. Chromosomal status of uni-pronuclear human zygotes following in-vitro fertilization and intracytoplasmic sperm injection. Hum Reprod 1995; 10:132-136.
39
40. Giorgetti C, Terriou P, Auquier P, Hans E, Spach JL, Salzmann J, et al. Implantation:Embryo score to predict implantation after in-vitro fertilization: based on 957 single embryo transfers. Hum Reprod 1995; 10: 2427-2431.
40
41. Terriou P, Giorgetti C, Hans E, Salzmann J, Charles O, Cignetti L, at al. Relationship between even early cleavage and day 2 embryo score and assessment of their predictive value for pregnancy. Reprod Biomed Online 2007; 14: 294-299.
41
42. Yang XY, Wang J, Liu JY, Gao Y, Zhou ZM, Sha JH, et al. Pregnancy outcome after intracytoplasmic sperm injection with strontium oocyte activation in a globozoospermic patient. Asian J Androl 2012; 14: 341-343.
42
43. Heindryckx B, De Gheselle S, Gerris J, Dhont M, De Sutter P. Efficiency of assisted oocyte activation as a solution for failed intracytoplasmic sperm injection. Reprod Biomed Online 2008; 17:662-668.
43
44. Heindryckx B, Van der Elst J, De Sutter P, Dhont M. Treatment option for sperm- or oocyte-related fertilization failure: assisted oocyte activation following diagnostic heterologous ICSI. Hum Reprod 2005; 20: 2237-2241.
44
46. Nasr-Esfahani MH, Deemeh MR, Tavalaee M. Artificial oocyte activation and intracytoplasmic sperm injection. Fertil Steril 2010; 94: 520-526.
45
46. Rybouchkin AV, Van der Straeten F, Quatacker J, De Sutter P, Dhont M. Fertilization and pregnancy after assisted oocyte activation and intracytoplasmic sperm injection in a case of round-headed sperm associated with deficient oocyte activation capacity. Fertil Steril 1997; 68: 1144-1147.
46
47. Kim JW, Kim SD, Yang SH, Yoon SH, Jung JH, Lim JH. Successful pregnancy after SrCl2 oocyte activation in couples with repeated low fertilization rates following calcium ionophore treatment. Syst Biol Reprod Med 2014; 60: 177-182.
47
48. Zhang D, Pan L, Yang LH, He XK, Huang XY, Sun FZ. Strontium promotes calcium oscillations in mouse meiotic oocytes and early embryos through InsP3 receptors, and requires activation of phospholipase and the synergistic action of InsP3. Hum Reprod 2005; 20: 3053-3061.
48
49. Grasa P1, Coward K, Young C, Parrington J. The pattern of localization of the putative oocyte activation factor, phospholipase Czeta, in uncapacitated, capacitated, and ionophore-treated human spermatozoa. Hum Reprod 2008; 23:2513-25122.
49
50. Kashir J, Jones C, Mounce G, Ramadan WM, Lemmon B, Heindryckx B, et al. Variance in total levels of phospholipase C zeta (PLC-ζ) in human sperm may limit the applicability of quantitative immunofluorescent analysis as a diagnostic indicator of oocyte activation capability. Fertil Steril 2013; 99:107-117.
50
51. Young C, Grasa P, Coward K, Davis LC, Parrington J. Phospholipase C zeta undergoes dynamic changes in its pattern of localization in sperm during capacitation and the acrosome reaction. Fertil Steril 2009; 9:2230-2242.
51
52. Tavalaee M, Nasr-Esfahani MH. Expression profile of PLCζ, PAWP, and TR-KIT in association with fertilization potential, embryo development, and pregnancy outcomes in globozoospermic candidates for intra-cytoplasmic sperm injection and artificial oocyte activation. Andrology 2016; 4: 850-856.
52
53. Heytens E, Parrington J, Coward K, Young C, Lambrecht S, Yoon SY, et al. Reduced amounts and abnormal forms of phospholipase C zeta (PLCzeta) in spermatozoa from infertile men. Hum Reprod 2009; 24: 2417-2428.
53
54. Swann K, Ozil JP. Dynamics of the calcium signal that triggers mammalian egg activation. Int Rev Cytol 1994; 152:183-222.
54
55. Tateno H, Kamiguchi Y. How long do parthenogenetically activated mouse oocytes maintain the ability to accept sperm nuclei as a genetic partner? J Assist Reprod Genet. 2005; 22: 89-93.
55
56. Nikiforaki D, Vanden Meerschaut F, de Roo C, Lu Y, Ferrer-Buitrago M, de Sutter P, et al. Effect of two assisted oocyte activation protocols used to overcome fertilization failure on the activation potential and calcium releasing pattern. Fertil Steril 2016; 105:798-806.
56
57. Bilodeau-Goeseels S. Cows are not mice: the role of cyclic AMP, phosphodiesterases, and adenosine monophosphate-activated protein kinase in the maintenance of meiotic arrest in bovine oocytes. Mol Reprod Dev 2011; 78: 734-743.
57
58. Hosseini SM, Hajian M, Moulavi F, Shahverdi AH, Nasr-Esfahani MH. Optimized combined electrical-chemical parthenogenetic activation for in vitro matured bovine oocytes. Anim Reprod Sci 2008; 108:122-33.
58
59. Schatten H, Sun QY. New insights into the role of centrosomes in mammalian fertilization and implications for ART. Reproduction 2011; 142:793-801.
59
60. Méo SC, Yamazaki W, Ferreira CR, Perecin F, Saraiva NZ, Leal CL, et al. Parthenogenetic activation of bovine oocytes using single and combined strontium, ionomycin and 6-dimethylaminopurine treatments. Zygote 2007; 15:295-306.
60
61. Rogers NT, Hobson E, Pickering S, Lai FA, Braude P, Swann K. Phospholipase Czeta causes Ca2+ oscillations and parthenogenetic activation of human oocytes. Reproduction 2004; 128: 697-702.
61
62. Chen J, Qian Y, Tan Y, Mima H. Successful pregnancy following oocyte activation by strontium in normozoospermic patients of unexplained infertility with fertilisation failures during previous intracytoplasmic sperm injection treatment. Reprod Fertil Dev 2010; 22:852-855.
62
63. Kyono K, Kumagai S, Nishinaka C, Nakajo Y, Uto H, Toya M, et al. Birth and follow-up of babies born following ICSI using SrCl2 oocyte activation. Reprod Biomed Online 2008; 17:53-58.
63
64. Tripathi A, Chaube SK. High cytosolic free calcium level signals apoptosis through mitochondria-caspase mediated pathway in rat eggs cultured in vitro. Apoptosis 2012; 17:439-448.
64
ORIGINAL_ARTICLE
The effects of bortezomib on the ovariectomy applied rat uterus: A histopathological, stereological and immunohistochemical study
Objective(s): In this study, potential protective effects of Bortezomib (Bort), as a proteasome inhibitor, were investigated on the uterus of ovariectomized rats by histological, morphometric and immunohistochemical methods.Materials and Methods: In this study, 18 Sprague dawley strain female rats (12 weeks old, 250-300 g body weight) were used. Animals in the control group (Cont, n=6) were not exposed to any treatment. Ovariectomy was performed on the experimental groups. They (n=12) were divided into ovariectomy (Ovt, n=6) and Bortezomib (Bort, n=6) subgroups. Twelve weeks later, the rats were perfused. Then, uterine tissues were removed and examined by morphometrical, and light and electron microscopy methods. In addition, immunoreactivity of nuclear factor-kappa (NF-κB) was evaluated.Results: Morphometric and histopathological evaluations showed that Bort was effective in the uterus and protects the layer structures and the cells.Conclusion: In the light of these findings, we suggest that for proteasome inhibitor particularly Bort is thought to be useful through proteasome inhibition and NF-κB pathway.
https://ijbms.mums.ac.ir/article_11546_f392db9030f233af4ece5140662beb4b.pdf
2018-11-01
1118
1125
10.22038/ijbms.2018.24756.6152
Bortezomib Microscopy Ovariectomy Rat Stereology
Uterus
Habib
Khoshvaghti
hkhoshvaghti@yandex.com
1
Department of Histology and Embryology, Medical Faculty, Bülent Ecevit University, Zonguldak, Turkey
LEAD_AUTHOR
Berrin Zuhal
Altunkaynak
berrinzuhal@gmail.com
2
Department of Histology and Embryology, Medical Faculty, İstanbul Okan University, İstanbul, Turkey
AUTHOR
1. Finch CE, Morgan DG. RNA and protein metabolism in the aging brain. Annu Rev Neurosci 1990; 13:75-88.
1
2. Hutter E, Renner K, Pfister G, Stockl P, Jansen-Durr P, Gnaiger E. Senescence-associated changes in respiration and oxidative phosphorylation in primary human fibroblasts. Biochem J 2004; 380:919-928.
2
3. Passos JF, Saretzki G, Ahmed S, Nelson G, Richter T, Peters H, et al. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol 2007; 5:110-123.
3
4. Zwerschke W, Mazurek S, Stockl P, Hutter E, Eigenbrodt E, Jansen-Durr P. Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence. Biochem J 2003; 376:403-411.
4
5. Cuervo AM, Dice JF. When lysosomes get old. Exp Gerontol 2000; 35:119-131.
5
6. Perichon R, Bourre J. Aging-related decrease in liver peroxisomal fatty acid oxidation in control and clofibrate-treated mice. A biochemical study and mechanistic approach. Mech Ageing Dev 1996; 87:115-126.
6
7. Popper H. Aging and the liver. Prog Liver Dis 1986; 8:659-683.
7
8. Masters CJ, Crane DI. On the role of the peroxisome in ontogeny, ageing and degenerative disease. Mech Ageing Dev 1995; 80:69-83.
8
9. Foster HA, Bridger JM. The genome and the nucleus: a marriage made by evolution. Genome organisation and nuclear architecture. Chromosoma 2005; 114:212-229.
9
10. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001; 21:245-273.
10
11. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107:241-246.
11
12. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappaB activation: From bench to bedside. Exp Biol Med 2008; 233:21-31.
12
13. Panwalkar A, Verstovsek S, Giles F. Nuclear Factor-KappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 2004; 100:1578-1589.
13
14. Lawrence T. The Nuclear Factor NF-κB Pathway in Inflammation. Cold Spring Harb Perspect Biol 2009; 1: a001651.
14
15. Barmparas G, Branco BC, Schnuriger B, Lam L, Inaba K, Demetriades D. The incidence and risk factors of post-laparotomy adhesive small bowel obstruction. J Gastrointest Surg 2010; 14:1619-1628.
15
16. Castelo-Branco C, Palacios S, Combalia J, Ferrer M, Traveria G. Risk of hypoactive sexual desire disorder and associated factors in a cohort of oophorectomized women. Climacteric 2009; 12:525-532.
16
17. Hayes MG, Urbanek M, Ehrmann DA, Armstrong LL, Lee JY, Sisk R, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun 2015; 6:7502.
17
18. Parker WH, Broder MS, Liu ZM, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Clin Obstet Gynecol 2007; 50:354-361.
18
19. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70:200-209.
19
20. Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int 2008; 14:111-116.
20
21. Dou QP, Zonder JA. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets 2014; 14:517-536.
21
22. Hilt W, Wolf DH. Proteasomes: Destruction as a programme. Trends Biochem Sci 1996; 21:96-102.
22
23. Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, et al. Abnormally high expression of proteasomes in human leukemic-cells. Proc Natl Acad Sci U S A 1990; 87:7071-7075.
23
24. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade™(Bortezomib). Cancer Invest 2004; 22:304-311.
24
25. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6:3719-3728.
25
26. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996-5000.
26
27. MacLaren AP, Chapman RS, Wyllie AH, Watson CJ. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001; 8: 210-218.
27
28. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82:110-122.
28
29. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-2622.
29
30. Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND. 150. Ann Oncol 2007; 18:116-121.
30
31. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
31
32. Richardson PG, Chanan-Khan A, Lonial S, Krishnan A, Carroll M, Alsina M, et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: Results of a phase 1/2 study. Br J Haematol 2011; 153:729-740.
32
33. Altunkaynak BZ, Önger ME, Altunkaynak ME, Ayranci E, Canan S. Brief introduction to stereology and sampling strategies: basic concepts of stereology. NeuroQuantology 2012; 10:31-43.
33
34. Altunkaynak BZ, Unal D, Altunkaynak ME, Halici Z, Kalkan Y, Keles ON, et al. Effects of diabetes and ovariectomy on rat hippocampus (a biochemical and stereological study). Gynecol Endocrinol 2012; 28:228-233.
34
35. Kalaycioglu A, Ucuncu Y, Altunkaynak BZ, Altunkaynak ME, Gundogdu C, Keles ON, et al. Stereological evaluation of the kidneys of anencephalic and normal fetuses. Ren Fail 2013; 35:110-117.
35
36. Dursun H, Albayrak F, Uyanik A, Keleş NO, Beyzagül P, Bayram E, et al. Effects of hypertension and ovariectomy on rat hepatocytes. Are amlodipine and lacidipine protective? (A stereological and histological study). TURK J Gastroenterol 2010; 21:387-395.
36
37. Driscoll JJ, Woodle ES. Targeting the ubiquitin+proteasome system in solid tumors. Semin Hematol 2012; 49:277-283.
37
38. Conrad C, Podolsky MJ, Cusack JC. Antiproteasomal agents in rectal cancer. Anticancer Drugs 2011; 22:341-350.
38
39. Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 2005; 11:5526-5533.
39
40. Veschini L, Belloni D, Foglieni C, Cangi MG, Ferrarini M, Caligaris-Cappio F, et al. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 2007; 109:2565-2570.
40
41. Sorollaa A, Yeramiana A, Vallsb J, Dolceta X, Bergadàa L, Llombart-Cussacc A, et al. Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. Mol Oncol 2012; 6:530-541.
41
42. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 2010; 150:428-437.
42
43. Unsal F, Sonmez MF. The effects of ovariectomy on ghrelin expression in the rat uterus. Adv Clin Exp Med 2014; 23:363-370.
43
44. Carbonel AAF, Baracat MCP, Simoes RS, Simoes MJ, Baracat EC, Soares JM. The soybean concentrated extract proliferates the vagina of adult rats. Menopause 2011; 18:93-101.
44
45. Fawcett DW, Deane HW. The effect of cortisone on uterine growth in ovariectomized rats receiving estradiol. Q J Microsc Sci 1951; 92:385-392.
45
46. Cevik O, Akpinar H, Oba R, Cilingir OT, Ozdemir ZN, Cetinel S, Yoldemir T. The effect of Momordica charantia intake on the estrogen receptors ESRα/ESRβ gene levels and apoptosis on uterine tissue in ovariectomy rats. Mol Biol Rep. 2015; 42: 167-177.
46
47. Rovillain E, Mansfield L, Caetano C, Alvarez-Fernandez M, Caballero OL, Medema RH, et al. Activation of nuclear factor-kappa B signalling promotes cellular senescence. Oncogene 2011; 30:2356-2366.
47
48. Adler AS, Sinha S, Kawahara TL, Zhang JY, Segal E, Chang HY. Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev 2007; 21:3244-3257.
48
49. Cullen S, Ponnappan U, Ponnappan S. Proteasome inhibition up-regulates inflammatory gene transcription induced by an atypical pathway of NF-κB activation. Biochem Pharmacol 2010; 79:706-714.
49
ORIGINAL_ARTICLE
Immunohistochemical characterization of pancreatic duodenal homeobox protein-1, neurogenin-3 and insulin protein expressions in islet-mesenchymal cell in vitro interactions from injured adult pancreatic tissues: a morphochronological evaluation
Objective(s): The use of a co-culture of islets with mesenchymal stromal cells (MSCs) is a promising therapy in islet transplantation to revert hyperglycaemia, but the resulting insulin-producing cells (IPCs) express low levels of pancreas endocrine developmental genes. This study aims to investigate the morphochronology of a co-culture of islets with MSCs from injured adult pancreata, and characterize pancreatic duodenal homeobox protein-1 (Pdx1), neurogenin-3 (Ngn3) and insulin protein expressions to establish the fate of their interaction. Materials and Methods: Islets and MSCs were isolated from sham operated control (SOC) and duct-ligated (PPDL) pancreata. Islets from SOC or PPDL tissues were cultured with or without MSCs in RPMI1640, supplemented by 1% Penicillin-Streptomycin, and maintained at 37 °C±1 °C at 95% relative humidity and 95% /5% air/CO2. Pdx1, Ngn3 and insulin expressions were determined by immunohistochemistry and islet morphochronological changes were assessed. Results: Pdx1 was expressed in all islet-cell cultures with or without MSCs. Pdx1+ islet cells were significantly increased in the presence of MSCs compared to the islet culture without MSCs. Similarly, Ngn3 was highly expressed in all cultures with MSCs from both SOC and PPDL tissues and the expression was prolonged in cultures using PPDL tissues before it was down-regulated, thereby, extending the period of Ngn3+ cell expansion and differentiation into mature functional islets. Conclusion: In vitro, MSCs maintain a pool of Ngn3+ that contributes to insulin production from mature beta cells but the activation of insulin production from non-beta cells may not be induced by direct signals from MSCs.
https://ijbms.mums.ac.ir/article_11576_17c795d801eef7d4fa5969025ce1b65d.pdf
2018-11-01
1126
1132
10.22038/ijbms.2018.26688.6536
Co-culture
Duct ligated pancreas
Insulin
Islet
MSC
NeuroG3
Pdx1
Transplantation
Juziel
Manda
jmanda@medcol.mw
1
Islet and MSK Research Group, Anatomy and Histology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Western Cape, South Africa
AUTHOR
Venant
Tchokonte-Nana
venant.tnana@gmail.com
2
Islet and MSK Research Group, Anatomy and Histology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Western Cape, South Africa
LEAD_AUTHOR
1. Chintinne M, Stangé G, Denys B, Ling Z, Pipeleers D. Beta cell count instead of beta cell mass to assess and localize growth in beta cell population following pancreatic duct ligation in mice. PLoS One 2012;7:e43959.
1
2. Xu X, D’Hoker J, Stange G, Bonne S, Leu N De, Xiao X, et al. β cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 2008;132:197–207.
2
3. Tchokonte-Nana V. Cellular mechanisms involved in the recapitulation of endocrine development in the duct ligated pancreas. Stellenbosch: University of Stellenbosch; 2011.
3
4. Inada A, Nienaber C, Katsuta H, Fujitani Y, Levine J, Morita R, et al. Carbonic anhydrase II-positive pancreatic cells are progenitors for both endocrine and exocrine pancreas after birth. Proc Natl Acad Sci U S A 2008;105:19915–19919.
4
5. Murtaugh LC, Kopinke D. Pancreatic stem cells. In Cambridge (MA): L. Charles Murtaugh and Daniel Kopinke; 2008. (StemBook).
5
6. Page BJ, du Toit DF, Muller CJ, Mattysen J, Lyners R, Arends E. Autogenous transplantation of a duct ligated pancreas: a functional and histological study. J Pancreas 2004;5:71–80.
6
7. Solar M, Cardalda C, Houbracken I, Martín M, Maestro MA, Medts N De, et al. Pancreatic exocrine duct cells give rise to insulin-producing β cells during embryogenesis but not after birth. Dev Cell 2009;17:849–60.
7
8. Wang RN, Klöppel G, Bouwens L. Duct-to islet-cell differentiation and islet growth in the pancreas of duct-ligated adult rats. Diabetologia 1995;38:1405–1411.
8
9. Kopp JL, Dubois CL, Schaffer AE, Hao E, Shih HP, Seymour PA, et al. Sox9+ ductal cells are multipotent progenitors throughout development but do not produce new endocrine cells in the normal or injured adult pancreas. Development 2011 ;138:653–665.
9
10. Cano DA, Rulifson IC, Heiser PW, Swigart LB, Pelengaris S, German M, et al. Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes. 2008 ;57:958–966.
10
11. Pagliuca FW, Melton DA. How to make a functional beta-cell. Development 2013 ;140:2472–2483.
11
12. Gittes GK, Galante PE, Hanahan D, Rutter WJ, Debase HT. Lineage-specific morphogenesis in the developing pancreas: role of mesenchymal factors. Development 1996 ;122:439–447.
12
13. Pictet RL, Clark WR, Williams RH, Rutter WJ. An ultrastructural analysis of the developing embryonic pancreas. Dev Biol 1972;29:436–467.
13
14. Kramer B, Andrew A, Rawdon BB, Becker P. The effect of pancreatic mesenchyme on the differentiation of endocrine cells from gastric endoderm. Development 1987 ;100:661–671.
14
15. Kedinger M, Simon-Assmann PM, Lacroix B, Marxer A, Hauri HP, Haffen K. Fetal gut mesenchyme induces differentiation of cultured intestinal endodermal and crypt cells. Dev Biol 1986;113:474–483.
15
16. Manda JK. An in vitro study of mesenchyme--islet cell interactions in islet neogenesis: A model for tissue replacement therapy in diabetes mellitus. Stellenbosch: Stellenbosch University; 2017.
16
17. Manda JK, Page BJ, Tchokonte-Nana V. Mesenchymal cells are required for epithelial duct cell-to-beta cell maturation and function in an injured adult pancreas in the rat. Acta Histochem 2017 1;119:689–695.
17
18. Yu K, Fischbach S, Xiao X. Beta Cell Regeneration in Adult Mice: Controversy Over the Involvement of Stem Cells. Curr Stem Cell Res Ther 2016;11:542–546.
18
19. Hogan BLM. Morphogenesis. Cell 1999;96:225–233.
19
20. Trott J, Tan EK, Ong S, Titmarsh DM, Denil SLIJ, Giam M, et al. Long-Term Culture of Self-renewing pancreatic progenitors derived from human pluripotent stem cells. Stem cell reports 2017;8:1675–1688.
20
21. Puri S, Hebrok M. Cellular plasticity within the pancreas-lessons learned from development. Dev Cell 2010;18:342–356.
21
22. Tchokonte-Nana V, Manda JK. Early islets and mesenchyme from an injured adult pancreas improve syngeneic engraftments and islet graft function in diabetic rats. Acta Histochem 2018;120:356-362.
22
23. Schauwer C De, Meyer E, Cornillie P, Vliegher S De, van de Walle GR, Hoogewijs M, et al. Optimization of the isolation, culture, and characterization of equine umbilical cord blood mesenchymal stromal cells. Tissue Eng Part C Methods 2011;17:1061–1070.
23
24. Ohlsson H, Karlsson K, Edlund T. IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J 1993;12:4251–4259.
24
25. Waeber G, Thompson N, Nicod P, Bonny C. Transcriptional activation of the GLUT2 gene by the IPF-1/STF-1/IDX-1 homeobox factor. Mol Endocrinol 1996;10:1327–1334.
25
26. Watada H, Kajimoto Y, Miyagawa J, Hanafusa T, Hamaguchi K, Matsuoka T, et al. PDX-1 induces insulin and glucokinase gene expressions in alphaTC1 clone 6 cells in the presence of betacellulin. Diabetes 1996;45:1826–1831.
26
27. Pedersen JK, Nelson SB, Jorgensen MC, Henseleit KD, Fujitani Y, Wright CVE, et al. Endodermal expression of Nkx6 genes depends differentially on Pdx1. Dev Biol 2005;288:487–501.
27
28. Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 2002;129:2447–2457.
28
29. Gros L, Montoliu L, Riu E, Lebrigand L, Bosch F. Regulated production of mature insulin by non-beta-cells. Hum Gene Ther 1997;8:2249–2259.
29
ORIGINAL_ARTICLE
The application of titanium dioxide (TiO2) nanoparticles in the photo-thermal therapy of melanoma cancer model
Objective(s): Photo-thermal therapy (PTT) is a therapeutic method in which photon energy is converted into heat to induce hyperthermia in malignant tumor cells. In this method, energy conversion is performed by nanoparticles (NPs) to enhance induced heat efficacy. The low-cytotoxicity and high optical absorbance of NPs used in this technique are very important. In the present study, titanium dioxide (TiO2) NPs were used as agents for PTT. For increasing water dispersibility and biocompatibility, polyethylene glycol (PEG)-TiO2 NPs (PEGylated TiO2 NPs) were synthesized and the effect of these NPs on reducing melanoma tumor size after PTT was experimentally assessed. Materials and Methods: To improve the dispersibility of TiO2 NPs in water, PEG was used for wrapping the surface of TiO2 NPs. The formation of a thin layer of PEG around the TiO2 NPs was confirmed through thermo-gravimetric analysis and transmission electron microscopy techniques. Forty female cancerous mice were divided into four equal groups and received treatment with NPs and a laser diode (λ = 808 nm, P = 2 W & I = 2 W/cm2) for seven min once in the period of the treatment. Results: Compared to the mice receiving only the laser therapy, the average tumor size in the mice receiving TiO2-PEG NPs with laser excitation treatment sharply decreased. Conclusion: The results of animal studies showed that PEGylated TiO2 NPs were exceptionally potent in destroying solid tumors in the PTT technique.
https://ijbms.mums.ac.ir/article_11547_90fa53ad6df7ebcc13f3c9d81de46e22.pdf
2018-11-01
1133
1139
10.22038/ijbms.2018.30284.7304
Hyperthermia
Laser diode
Melanoma cancer
PEGylated titanium dioxide (TiO2-PEG) nanoparticles Photo-thermal therapy
Mohammad Ali
Behnam
m.behnam@sutech.ac.ir
1
Nano Opto-Electronic Research Center, Electrical and Electronics Engineering Department, Shiraz University of Technology, Shiraz, Iran
AUTHOR
Farzin
Emami
emami@sutech.ac.ir
2
Nano Opto-Electronic Research Center, Electrical and Electronics Engineering Department, Shiraz University of Technology, Shiraz, Iran
AUTHOR
Zahra
Sobhani
sobhani@sums.ac.ir
3
Quality Control Department, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
Amir Reza
Dehghanian
adehghan@sums.ac.ir
4
Pathology Department, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
1. Ortiz R, Melguizo C, Prados J, Alvarez PJ, Caba O, Rodriguez-Serrano F, et al. New gene therapy strategies for cancer treatment: a review of recent patents. Recent Pat Anticancer Drug Discov 2012; 7:297–312.
1
2. Bertrand N, Leroux J-CC. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release 2012; 161:152–163.
2
3. Behnam MA, Emami F, Sobhani Z, Koohi-Hosseinabadi O, Dehghanian AR, Zebarjad SM, et al. Novel combination of silver nanoparticles and carbon nanotubes for plasmonic photo thermal therapy in melanoma cancer model. Adv Pharm Bull 2018; 8:49-55.
3
4. Moosavi Nejad S, Takahashi H, Hosseini H, Watanabe A, Endo H, Narihira K, et al. Acute effects of sono-activated photocatalytic titanium dioxide nanoparticles on oral squamous cell carcinoma. Ultrason Sonochem 2016; 32:95–101.
4
5. Yin ZF, Wu L, Yang HG, Su YH. Recent progress in biomedical applications of titanium dioxide. Phys Chem Chem Phys 2013; 15:4844–4858.
5
6. Bibin AB, Kume K, Tsutumi K, Fukunaga Y, Ito S, Imamura Y, et al. Observation the distribution of titanium dioxide nano-particles in an experimental tumor tissue by a raman microscope. AIP Conf Proc 2011; 55–58.
6
7. Uehara M, Ikeda H, Nonaka M, Sumita Y, Nanashima A, Nonaka T, et al. Predictive factor for photodynamic therapy effects on oral squamous cell carcinoma and oral epithelial dysplasia. Arch Oral Biol 2011; 56:1366–1372.
7
8. Yakunin AN, Avetisyan Y, Tuchin VV. Quantification of laser local hyperthermia induced by gold plasmonic nanoparticles. J Biomed Opt 2015; 20:51030–51030.
8
9. Thompson EA, Graham E, Macneill CM, Young M, Donati G, Wailes EM, et al. Differential response of MCF7, MDA-MB-231, and MCF 10A cells to hyperthermia, silver nanoparticles and silver nanoparticle-induced photothermal therapy. Int J Hyperthermia 2014; 30:312–323.
9
10. Sobhani Z, Behnam MA, Emami F, Dehghanian A, Jamhiri I. Photothermal therapy of melanoma tumor using multiwalled carbon nanotubes. Int J Nanomedicine 2017; 12:4509–4517.
10
11. Jhuang YY, Cheng WT. Fabrication and characterization of silver/titanium dioxide composite nanoparticles in ethylene glycol with alkaline solution through sonochemical process. Ultrason Sonochem 2016; 28:327–333.
11
12. Eskandarloo H, Badiei A, Behnajady MA, Ziarani GM. Ultrasonic-assisted sol-gel synthesis of samarium, cerium co-doped TiO2 nanoparticles with enhanced sonocatalytic efficiency. Ultrason Sonochem 2015; 26:281–292.
12
13. Jugan ML, Barillet S, Simon-Deckers A, Sauvaigo S, Douki T, Herlin N, et al. Cytotoxic and genotoxic impact of TiO2 nanoparticles on A549 cells. J Biomed Nanotechnol 2011; 7:22–23.
13
14. Carp O, Huisman CL, Reller A. Photoinduced reactivity of titanium dioxide. Prog Solid State Chem 2004; 32:33–177.
14
15. Haseeb A, Hasan MM, Masjuki HH. Structural and mechanical properties of nanostructured TiO2 thin films deposited by RF sputtering. Surf Coat Technol 2010; 205:338–344.
15
16. He Q, Wen X, Ma P, Deng X. Alkali induced morphology and property improvements of TiO2 by hydrothermal treatment. J Wuhan University Tech-Mater. Sci. Ed 2008; 23:503–506.
16
17. Tanner K E. Titanium in medicine. Proc Inst Mech Eng H 2016; 216:215-215.
17
18. Devanand Venkatasubbu G, Ramasamy S, Ramakrishnan V, Kumar J. Folate targeted PEGylated titanium dioxide nanoparticles as a nanocarrier for targeted paclitaxel drug delivery. Adv Powder Technol 2013; 24:947–954.
18
19. Yamaguchi S, Kobayashi H, Narita T, Kanehira K, Sonezaki S, Kudo N, et al. Sonodynamic therapy using water-dispersed TiO2-polyethylene glycol compound on glioma cells: comparison of cytotoxic mechanism with photodynamic therapy. Ultrason Sonochem 2011; 18:1197–1204.
19
20. Wang R, Hashimoto K, Fujishima A, Chikuni M, Kojima E, Kitamura A, et al. Light-induced amphiphilic surfaces. Nature 1997; 388:431–432.
20
21. Xu P, Wang R, Ouyang J, Chen B. A new strategy for TiO2 whiskers mediated multi-mode cancer treatment. Nanoscale Res Lett 2015; 10:94–104.
21
22. Ren W, Zeng L, Shen Z, Xiang L, Gong A, Zhang J, et al. Enhanced doxorubicin transport to multidrug resistant breast cancer cells via TiO2 nanocarriers. RSC Adv 2013; 3:20855–20855.
22
23. Liu E, Zhou Y, Liu Z, Li J, Zhang D, Chen J, et al. Cisplatin loaded hyaluronic acid modified TiO2 nanoparticles for neoadjuvant chemotherapy of ovarian cancer. J Nanomater 2015; 2015:1–8.
23
24. Zhang Z, Wang J, Nie X, Wen T, Ji Y, Wu X, et al. Near infrared laser-induced targeted cancer therapy using thermoresponsive polymer encapsulated gold nanorods. J Am Chem Soc 2014; 136:7317–7326.
24
25. Brownell J, Wang S, Tsoukas MM. Phototherapy in cosmetic dermatology. Clin Dermatol 2016; 34:623–627.
25
26. Narayanan DL, Saladi RN, Fox JL. Review: ultraviolet radiation and skin cancer. Int J Dermatol 2010; 49:978–986.
26
27. Jiao Z, Chen Y, Wan Y, Zhang H. Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles. Int J Nanomedicine 2011; 6:2321–2326.
27
28. Li Q, Wang X, Lu X, Tian H, Jiang H, Lv G, et al. The incorporation of daunorubicin in cancer cells through the use of titanium dioxide whiskers. Biomaterials 2009; 30:4708–4715.
28
29. López T, Sotelo J, Navarrete J, Ascencio JA. Synthesis of TiO2 nanostructured reservoir with temozolomide: structural evolution of the occluded drug. Opt Mater 2006; 29:88–94.
29
30. Kim C, Kim S, Oh WK, Choi M, Jang J. Efficient intracellular delivery of camptothecin by silica/titania hollow nanoparticles. Chemistry 2012; 18:4902–4908.
30
31. Mano SS, Kanehira K, Sonezaki S, Taniguchi A. Effect of polyethylene glycol modification of TiO2 nanoparticles on cytotoxicity and gene expressions in human cell lines. Int J Mol Sci 2012; 13:3703–3717.
31
32. Naghibi S, Madaah Hosseini HR, Faghihi Sani MA, Shokrgozar MA, Mehrjoo M. Mortality response of folate receptor-activated, PEG-functionalized TiO2 nanoparticles for doxorubicin loading with and without ultraviolet irradiation. Ceram Int 2014; 40:5481–5488.
32
33. Du Y, Ren W, Li Y, Zhang Q, Zeng L, Chi C, et al. The enhanced chemotherapeutic effects of doxorubicin loaded PEG coated TiO2 nanocarriers in an orthotopic breast tumor bearing mouse model. J Mater Chem B 2015; 3:1518–1528.
33
34. Sowa P, Rutkowska-Talipska J, Sulkowska U, Rutkowski K, Rutkowski R. Electromagnetic radiation in modern medicine: physical and biophysical properties. Ann Med 2012; 19:139–142.
34
35. Sowa P, Rutkowska-Talipska J, Rutkowski K, Kosztyła-Hojna B, Rutkowski R. Optical radiation in modern medicine. Postepy Dermatol Alergol 2013; 30:246–251.
35
36. Penjweini R, Mokmeli S, Becker K, Dodt H-U, Saghafi S. Effects of UV-, visible-, near-infrared beams in three therapy resistance case studies of fungal skin infections. Optics Photonics J 2013; 3:1–10.
36
37. Bashkatov AN, Genina EA, Tuchin V V. Optical properties of skin, subcutaneous, and muscle tissues: a review. J Innov Opt Health Sci 2011; 4:9–38.
37
38. Juzeniene A, Brekke P, Dahlback A, Andersson-Engels S, Reichrath J, Moan K, et al. Solar radiation and human health. Rep Prog Phys 2011; 74:66701–66757.
38
39. Polefka TG, Meyer T a, Agin PP, Bianchini RJ. Effects of solar radiation on the skin. J Cosmet Dermatol 2012; 11:134–143.
39
40. Huang X, El-Sayed M a. Plasmonic photo-thermal therapy (PPTT). Alexandria J Med 2011; 47:1–9.
40
41. Huang X, El-Sayed M a. Gold nanoparticles: optical properties and implementations in cancer diagnosis and photothermal therapy. J Adv Res 2010; 1:13–28.
41
42. Vinardell M, Mitjans M. Antitumor activities of metal oxide nanoparticles. Nanomaterials 2015; 5:1004–1021.
42
43. Kwatra D, Venugopal A, Anant S. Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer. Transl Cancer Res 2013; 2:330–342.
43
44. Filonov GS, Piatkevich KD, Ting L-MM, Zhang J, Kim K, Verkhusha VV. Bright and stable near-infrared fluorescent protein for in vivo imaging. Nat Biotechnol 2011; 29:757–761.
44
45. Shcherbakova DM, Verkhusha VV. Near-infrared fluorescent proteins for multicolor in vivo imaging. Nat Methods 2013; 10:751–754.
45
46. Ni W, Li M, Cui J, Xing Z, Li Z, Wu X, et al. 808 nm light triggered black TiO2 nanoparticles for killing of bladder cancer cells. Mater Sci Eng C Mater Biol Appl 2017; 81:252–260.
46
47. Petković J, Küzma T, Rade K, Novak S, Filipič M. Pre-irradiation of anatase TiO2 particles with UV enhances their cytotoxic and genotoxic potential in human hepatoma HepG2 cells. J Hazard Mater 2011; 196:145–152.
47
ORIGINAL_ARTICLE
Serum-based metabolic alterations in patients with papillary thyroid carcinoma unveiled by non-targeted 1H-NMR metabolomics approach
Objective(s): As the most prevalent endocrine system malignancy, papillary thyroid carcinoma had a very fast rising incidence in recent years for unknown reasons besides the fact that the current methods in thyroid cancer diagnosis still hold some limitations. Therefore, the aim of this study was to improve the potential molecular markers for diagnosis of benign and malignant thyroid nodules to prevent unnecessary surgeries for benign tumors. Materials and Methods: In this study, 1H-NMR metabolomics platform was used to seek the discriminating serum metabolites in malignant papillary thyroid carcinoma (PTC) compared to benign multinodular goiter (MNG) and healthy subjects and also to better understand the disease mechanisms using bioinformatics analysis. Multivariate statistical analysis showed that PTC and MNG samples could be successfully discriminated in PCA and OPLS-DA score plots. Results: Significant metabolites that differentiated malignant and benign thyroid lesions included citrate, acetylcarnitine, glutamine, homoserine, glutathione, kynurenine, nicotinic acid, hippurate, tyrosine, tryptophan, β-alanine, and xanthine. The significant metabolites in the PTC group compared to healthy subjects also included scyllo- and myo-inositol, tryptophan, propionate, lactate, homocysteine, 3-methyl glutaric acid, asparagine, aspartate, choline, and acetamide. The metabolite sets enrichment analysis demonstrated that aspartate metabolism and urea cycle were the most important pathways in papillary thyroid cancer progression. Conclusion: The study results demonstrated that serum metabolic fingerprinting could serve as a viable method for differentiating various thyroid lesions and for proposing novel potential markers for thyroid cancers. Obviously, further studies are needed for the validation of the results.
https://ijbms.mums.ac.ir/article_11474_ae4f95cc24386feb8d8177c9c564043f.pdf
2018-11-01
1140
1147
10.22038/ijbms.2018.30375.7323
Metabolomics
Multinodular goiter
NMR
Serum
Thyroid cancer
Reyhaneh
Farrokhi Yekta
r_farrokhi@sbmu.ac.ir
1
Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Mostafa
Rezaei Tavirani
tavirany@yahoo.com
2
Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Afsaneh
Arefi Oskuie
a.arefi@sbmu.ac.ir
3
Department of Basic Sciences, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Mohamad Reza
Mohajeri Tehrani
mrmohajeri@tums.ac.ir
4
3 Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Ahmad Reza
Soroush
sorosham@tums.ac.ir
5
Department of Surgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Alireza
Akbarzadeh Baghban
akbarzad@gmail.com
6
Department of Basic Sciences, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
1. Jia-XiangW, Jie-kai Y, Li W, Qiu-Liang L, Jiao Z, Shu Z. Application of serum protein fingerprint in diagnosis of papillary thyroid carcinoma. Proteomics 2006; 6:5344-5349.
1
2. Tian Y, Nie X, Xu S, Li Y, Huang T, Tang H, et al. Integrative metabonomics as potential method for diagnosis of thyroid malignancy. Sci Rep 2015; 14869:1-12.
2
3. Wojakowska A, Chekan M, Widlak P, Pietrowska M. Application of metabolomics in thyroid cancer research. Int J Endocrinol 2015; 2015:1-13.
3
4. Lupoli G, Fonderico F, Colarusso S, Panico A, Cavallo A, Micco LD, et al. Current management of differentiated thyroid carcinoma. Med Sci Monit 2005; 11:368-373.
4
5. Castro MR, Gharib H. Thyroid fine-needle aspiration biopsy: Progress, practice, and pitfalls. Endocr pract 2003; 9:128–136.
5
6. Ringel MD. Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma. Rev Endocr Metab Disord 2000; 1:173–181.
6
7. Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med 2008; 132:359-372.
7
8. Farrokhi Yekta R, Rezaie Tavirani M, Arefi Oskouie A, Mohajeri-Tehrani MR, Soroush AR. The metabolomics and lipidomics window into thyroid cancer research. Biomarkers 2017; 22:595-603.
8
9. Nobakht MGBF, Aliannejad R, Rezaei-Tavirani M, Taheri S, Oskouie AA. The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis. Biomarkers 2015; 20:5-16.
9
10. Safaei A, Arefi Oskouie A, Mohebbi SR, Rezaei-Tavirani M, Mahboubi M, Peyvandi M, et al. Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases. Gastroenterol Hepatol Bed Bench 2016; 9:158-173.
10
11. Ulrich E, Akutsu H, Doreleijers JF, Harano Y, Ioannidis YE, Lin Y, et al. BioMagResBank. Nucl Acids Res 2008; 36:D402-D408.
11
12. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0--The human metabolome database in 2013. Nucleic Acids Res 2013; 41:D801-807.
12
13. Xia J, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3.0--making metabolomics more meaningful. Nucleic Acids Res 2015; 43:W251-257.
13
14. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13:2498-2504.
14
15. Karnovsky A, Weymouth T, Hull T, Tarcea VG, Scardoni G, Laudanna C, et al. Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. Bioinformatics 2012; 28:373-380.
15
16. Hu ZZ, Huang H, Wu CH, Jung M, Dritschilo A, Riegel AT, et al. Omics-based molecular target and biomarker identification. Methods Mol Biol 2011; 719:547-571.
16
17. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 2010; 6:78-95.
17
18. Liu SY, Zhang RL, Kang H, Fan ZJ, Du Z. Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2013; 19:3423-3432.
18
19. Yao Z, Yin P, Su D, Peng Z, Zhou L, Ma L, et al. Serum metabolic profiling and features of papillary thyroid carcinoma and nodular goiter. Mol BioSyst 2011; 7:2608–2614.
19
20. Otto AM. Warburg effect(s)—a biographical sketch of Otto Warburg and his impacts on tumor metabolism. Cancer & Metabolism 2016; 4:1-8.
20
21. Kubota A, Meguid MM, Hitch DC. Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors. Cancer 1992; 69:2343-2348.
21
22. Nagamani SCS, Erez A. A metabolic link between the urea cycle and cancer cell proliferation. Mol Cell Oncol 2016; 3:e1127314.
22
23. Gu Y, Chen T, Fu S, Sun X, Wang L, Wang J, et al. Perioperative dynamics and significance of amino acid profiles in patients with cancer. J Transl Med 2015; 13:1-14.
23
24. Xu Y, Zheng X, Qiu Y, Jia W, Wang J, Yin S. Distinct metabolomic profiles of papillary thyroid carcinoma and benign thyroid adenoma. J Proteome Res 2015; 14:3315-3321.
24
25. Deja S, Dawiskiba T, Balcerzak W, Orczyk-Pawiłowicz M, Głód M, Pawełka D, et al. Follicular adenomas exhibit a unique metabolic profile. 1H NMR studies of thyroid lesions. PLoS ONE 2013; 8:e84637.
25
26. Torregrossa L, Shintu L, Chandran JN, Tintaru A, Ugolini C, Magalhães A, et al. Toward the Reliable Diagnosis of Indeterminate Thyroid Lesions: A HRMAS NMR-Based Metabolomics Case of Study. J Proteome Res 2012; 11:3317-3325.
26
27. Miccoli P, Torregrossa L, Shintu L, Magalhaes A, Chandran JN, Tintaru A, et al. Metabolomics approach to thyroid nodules: A high-resolution magic-angle spinning nuclear magnetic resonance–based study. Surgery 2012; 152:1118-1124.
27
28. Rodrigues D, Monteiro M, Jerónimo C, Henrique R, Belo L, Bastos ML, et al. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems. Transl Res 2016; 180:1-11.
28
29. Giskeødegård GF, Hansen AF, Bertilsson H, Gonzalez SV, Kristiansen KA, Bruheim P, et al. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia. Br J Cancer 2015; 113:1712-1719.
29
30. Russell P, Lean CL, Delbridge L, May GL, Dowd S, Mountford CE. Proton magnetic resonance and human thyroid neoplasia I: Discrimination between benign and malignant neoplasms. Am J Med 1994; 96:383-388.
30
31. Ferruzzi E, Franceschinia R, Cazzolatob G, Geronic C, Fowstc C, Pastorinod U, et al. Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck. Eur J Cancer 2003; 39:1019-1029.
31
32. Iyamu EW. The redox state of the glutathione/glutathione disulfide couple mediates intracellular arginase activation in HCT-116 colon cancer cells. Dig Dis Sci 2010; 55:2520-2528.
32
33. Eng CH, Yu K, Lucas J, White E, Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci Signal 2010; 3:ra31.
33
34. Meng M, Chen S, Lao T, Liang D, Sang N. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. Cell Cycle 2010; 9:3921–3932.
34
35. Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells?. Cell Cycle 2010; 9:3884-3886.
35
ORIGINAL_ARTICLE
Interaction of aquaporin 4 and N-methyl-D-aspartate NMDA receptor 1 in traumatic brain injury of rats
Objective(s): -methyl-D-aspartate NMDA receptor (NMDAR) and aquaporin 4 (AQP4) are involved in the molecular cascade of edema after traumatic brain injury (TBI) and are potential targets of studies in pharmacology and medicine. However, their association and interactions are still unknown.Materials and Methods: We established a rat TBI model in this study. The cellular distribution patterns of AQP4 after inhibition of NMDAR were determined by Western blotting and immunoreactive staining. Furthermore, the regulation of NMDA receptor 1 by AQP4 was studied by injection of a viral vector targeting AQP4 by RNAi into the rat brain before TBI.Results: The results suggest that AQP4 protein expression increased significantly (P<0.05) after TBI and was down-regulated by the NMDAR inhibitor MK801. This decrease could be partly reversed using the NMDAR agonist NMDA. This indicated that AQP4 mRNA levels and protein expression are regulated by the NMDA signaling pathway. By injection of AQP4 RNAi viral vector into the brain of TBI rat models, we found that the mRNA and protein levels of NMDAR decreased significantly (P<0.05). This suggested that NMDAR is also regulated by AQP4.Conclusion: These data suggested that the inhibition of AQP4 down-regulates NMDAR expression, which might be one of the mechanisms involved in edema after TBI.
https://ijbms.mums.ac.ir/article_11439_b0ba5b77711055f91a820623d46ce70b.pdf
2018-11-01
1148
1154
10.22038/ijbms.2018.29135.7037
Aquaporin 4
Edema
N-methyl-D-aspartate
NMDA receptor
NMDAR1
Traumatic brain injury
Li-Hua
Chen
13801187508@sina.cn
1
The Affiliated Bayi Brain Hospital, The PLA Army General Hospital, Beijing 100700, China
AUTHOR
Hong-Tian
Zhang
zhanghongtian007@126.com
2
The Affiliated Bayi Brain Hospital, The PLA Army General Hospital, Beijing 100700, China
AUTHOR
Ru-Xiang
Xu
cnruxiangxu@126.com
3
The Affiliated Bayi Brain Hospital, The PLA Army General Hospital, Beijing 100700, China
LEAD_AUTHOR
Wen-De
Li
wenwendege@126.com
4
The Affiliated Bayi Brain Hospital, The PLA Army General Hospital, Beijing 100700, China
AUTHOR
Hao
Zhao
zh_zhaohao@163.com
5
The Affiliated Bayi Brain Hospital, The PLA Army General Hospital, Beijing 100700, China
AUTHOR
Yi
Yang
yangyi_81nk@163.com
6
The Affiliated Bayi Brain Hospital, The PLA Army General Hospital, Beijing 100700, China
AUTHOR
Kai
Sun
978307981@qq.com
7
The Affiliated Bayi Brain Hospital, The PLA Army General Hospital, Beijing 100700, China
AUTHOR
1. Tolias CM, Bullock MR. Critical appraisal of neuroprotection trials in head injury: what have we learned? NeuroRx 2004;1:71-79.
1
2. Schouten JW. Neuroprotection in traumatic brain injury: a complex struggle against the biology of nature. Curr Opin Crit Care 2007;13:134-142.
2
3. Quillinan N, Herson PS, Traystman RJ. Neuropathophysiology of brain injury. Anesthesiol Clin 2016;34:453-464.
3
4. Carvajal FJ, Mattison HA, Cerpa W. Role of NMDA receptor-rediated glutamatergic signaling in chronic and acute europathologies. Neural Plast 2016;2016:2701526.
4
5. McIntosh TK, Vink R, Soares H, Hayes R, Simon R. Effect of noncompetitive blockade of N-methyl-D-aspartate receptors on the neurochemical sequelae of experimental brain injury. J Neurochem 1990;55:1170-1179.
5
6. Biegon A, Fry PA, Paden CM, Alexandrovich A, Tsenter J, Shohami E. Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: Implications for treatment of neurological and cognitive deficits. Proc Natl Acad Sci U S A 2004;101:5117-5122.
6
7. Badaut J, Lasbennes F, Magistretti PJ, Regli L. Aquaporins in brain: distribution, physiology, and pathophysiology. J Cereb Blood Flow Metab 2002;22:367-378.
7
8. Xu M, Su W, Xu QP. Aquaporin-4 and traumatic brain edema. Chin J Traumatol 2010;13:103-110.
8
9. Papadopoulos MC, Verkman AS. Aquaporin-4 and brain edema. Pediatr Nephrol 2007;22:778-784.
9
10. Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989;244:798-800.
10
11. Verkman AS. Applications of aquaporin inhibitors. Drug News Perspect 2001;14:412-420.
11
12. Vizuete ML, Venero JL, Vargas C, Ilundáin AA, Echevarría M, Machado A, et al. Differential upregulation of aquaporin-4 mRNA expression in reactive astrocytes after brain injury: potential role in brain edema. Neurobiol Dis 1999;6:245-258.
12
13. Zhang C, Chen J, Lu H. Expression of aquaporin-4 and pathological characteristics of brain injury in a rat model of traumatic brain injury. Mol Med Rep 2015;12:7351-7357.
13
14. Gunnarson E, Zelenina M, Axehult G, Song Y, Bondar A, Krieger P, et al. Identification of a molecular target for glutamate regulation of astrocyte water permeability. Glia 2008;56:587-596.
14
15. Clark RS, Schiding JK, Kaczorowski SL, Marion DW, Kochanek PM. Neutrophil accumulation after traumatic brain injury in rats: comparison of weight drop and controlled cortical impact models. J Neurotrauma 1994;11:499-506.
15
16. Chen JQ, Zhang CC, Jiang SN, Lu H, Wang W. Effects of Aquaporin 4 knockdown on brain edema of the uninjured side after traumatic brain injury in rats. Med Sci Monit 2016;22:4809-4819.
16
17. Shapira Y, Shohami E, Sidi A, Soffer D, Freeman S, Cotev S. Experimental closed head injury in rats: mechanical, pathophysiologic, and neurologic properties. Crit Care Med 1988;16:258-265.
17
18. Zhang M, Cui Z, Cui H, Cao Y, Zhong C, Wang Y. Astaxanthin alleviates cerebral edema by modulating NKCC1 and AQP4 expression after traumaticbrain injury in mice. BMC Neurosci 2016;17:60.
18
19. Unterberg AW, Stover J, Kress B, Kiening KL. Edema and brain trauma. Neuroscience 2004;129:1021-1029.
19
20. Bareyre F, Wahl F, McIntosh TK, Stutzmann JM. Time course of cerebral edema after traumatic brain injury in rats: effects of riluzole and mannitol. J Neurotrauma 1997;14:839-849.
20
21. Blixt J, Svensson M, Gunnarson E, Wanecek M. Aquaporins and blood-brain barrier permeability in early edema development after traumatic brain injury. Brain Res 2015;1611:18-28.
21
22. Bernert H, Turski L. Traumatic brain damage prevented by the non-N-methyl-D-aspartate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f] quinoxaline. Proc Natl Acad Sci U S A 1996;93:5235-5240.
22
23. Goebel DJ, Poosch MS. NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A. Brain Res Mol Brain Res 1999;69:164-170.
23
24. Chen JH, Yang LK, Chen L, Wang YH, Wu Y, Jiang BJ, et al. Atorvastatin ameliorates early brain injury after subarachnoid hemorrhage via inhibition of AQP4 expression in rabbits. Int J Mol Med 2016;37:1059-1066.
24
25. Lieberman DN, Mody I. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature 1994;369:235-239.
25
ORIGINAL_ARTICLE
Generation of motor neurons from human amygdala-derived neural stem-like cells
Objective(s): Among several cell sources, adult human neural stem/progenitor cells (hNS/PCs) have been considered outstanding cells for performing mechanistic studies in in vitro and in vivo models of neurological disorders as well as for potential utility in cell-based therapeutic approaches. Previous studies addressed the isolation and culture of hNS/PCs from human neocortical and hippocampal tissues. However, little data are available on hNS/PCs obtained from the adult human amygdala.Materials and Methods: The present study explored the capacity of the amygdala harvested from resected brain tissues of patients with medically refractory epilepsy to generate neurosphere-like bodies and motor neuron-like cells.Results: Although the proliferation process was slow, a considerable amount of cells was obtained after the 3rd passage. In addition, the cells could generate motor neuron-like cells under appropriate culture conditions. Conclusion: Isolation and culture of these cells enable us to improve our knowledge of the role of the amygdala in some neurological and psychological disorders and provide a novel source for therapeutic cell transplantation.
https://ijbms.mums.ac.ir/article_11548_a7bde3b2eda8806114262f5bd4e373cf.pdf
2018-11-01
1155
1160
10.22038/ijbms.2018.29587.7146
Brain
Hippocampus
Intractable epilepsy
Motor Neuron
Neural stem cells
Sepideh
Ghasemi
s.ghasemi20@gmail.com
1
Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
AUTHOR
Hadi
Aligholi
hadialigholi@yahoo.com
2
Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Pir Hossain
Koulivand
peirhossein@yahoo.com
3
Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
AUTHOR
Maryam
Jafaraian
jafarian.m34@gmail.com
4
Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
AUTHOR
Hassan
Hosseini Ravandi
hasan60hosseini.r@gmail.com
5
Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
AUTHOR
Maryam
Khaleghi Ghadiri
maryam.khaleghighadiri@ukmuenster.de
6
Department of Neurosurgery, Westfälische Wilhelms-Universität Münster, Münster, Germany
AUTHOR
Ali
Gorji
gorjial@uni-muenster.de
7
Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
LEAD_AUTHOR
1. Kennea NL, Mehmet H. Neural stem cells. J Pathol 2002;197:536-550.
1
2. Vescovi AL, Parati EA, Gritti A, Poulin P, Ferrario M, Wanke E, Frölichsthal-Schoeller P, Cova L, Arcellana-Panlilio M, Colombo A, Galli R. Isolation and cloning of multipotential stem cells from the embryonic human CNS and establishment of transplantable human neural stem cell lines by epigenetic stimulation. Exp Neurol 1999;156:71-83.
2
3. Pollard SM, Conti L, Sun Y, Goffredo D, Smith A. Adherent neural stem (NS) cells from fetal and adult forebrain. Cereb Cortex 2006;16 Suppl 1:i112-120.
3
4. McLaren A. Ethical and social considerations of stem cell research. Nature 2001;414:129-131.
4
5. Delcroix GJ, Schiller PC, Benoit JP, Montero-Menei CN. Adult cell therapy for brain neuronal damages and the role of tissue engineering. Biomaterials 2010;31:2105-2120.
5
6. Taupin P, Gage FH. Adult neurogenesis and neural stem cells of the central nervous system in mammals. J Neurosci Res 2002;69:745-749.
6
7. Aligholi H, Hassanzadeh G, Azari H, Rezayat SM, Mehr SE, Akbari M, Attari F, Khaksarian M, Gorji A. A new and safe method for stereotactically harvesting neural stem/progenitor cells from the adult rat subventricular zone. J Neurosci Methods 2014;225:81-89.
7
8. Aligholi H, Rezayat SM, Azari H, Ejtemaei Mehr S, Akbari M, Modarres Mousavi SM, Attari F, Alipour F, Hassanzadeh G, Gorji A. Preparing neural stem/progenitor cells in PuraMatrix hydrogel for transplantation after brain injury in rats: A comparative methodological study. Brain Res 2016;1642:197-208.
8
9. Kokoeva MV, Yin H, Flier JS. Evidence for constitutive neural cell proliferation in the adult murine hypothalamus. J Comp Neurol 2007;505:209-220.
9
10. Sahab Negah S, Khooei A, Samini F, Gorji A. Laminin-derived Ile-Lys-Val-ala-Val: a promising bioactive peptide in neural tissue engineering in traumatic brain injury. Cell Tissue Res 2018;371:223-236.
10
11. Arsenijevic Y, Villemure JG, Brunet JF, Bloch JJ, Déglon N, Kostic C, Zurn A, Aebischer P. Isolation of multipotent neural precursors residing in the cortex of the adult human brain. Exp Neurol 2001;170:48-62.
11
12. Pagano SF, Impagnatiello F, Girelli M, Cova L, Grioni E, Onofri M, Cavallaro M, Etteri S, Vitello F, Giombini S, Solero CL, Parati EA. Isolation and characterization of neural stem cells from the adult human olfactory bulb. Stem Cells 2000;18:295-300.
12
13. Sanai N, Tramontin AD, Quiñones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S, Lawton MT, McDermott MW, Parsa AT, Manuel-García Verdugo J, Berger MS, Alvarez-Buylla A. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 2004;427:740-744.
13
14. Johansson CB, Svensson M, Wallstedt L, Janson AM, Frisén J. Neural stem cells in the adult human brain. Exp Cell Res 1999;253:733-736.
14
15. Kukekov VG, Laywell ED, Suslov O, Davies K, Scheffler B, Thomas LB, O’Brien TF, Kusakabe M, Steindler DA. Multipotent stem/progenitor cells with similar properties arise from two neurogenic regions of adult human brain. Exp Neurol 1999;156:333-344.
15
16. Nunes MC, Roy NS, Keyoung HM, Goodman RR, McKhann G 2nd, Jiang L, Kang J, Nedergaard M, Goldman SA. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med 2003;9:439-447.
16
17. Negah SS, Aligholi H, Khaksar Z, Kazemi H, Mousavi SM, Safahani M, Dowom PB, Gorji A. Survival, proliferation, and migration of human meningioma stem-like cells in a nanopeptide scaffold. Iran J Basic Med Sci 2016;19:1271-1278.
17
18. Seymour B, Dolan R. Emotion, decision making, and the amygdala. Neuron 2008;58:662-671.
18
19. Gloor P, Olivier A, Quesney LF, Andermann F, Horowitz S. The role of the limbic system in experiential phenomena of temporal lobe epilepsy. Ann Neurol 1982;12:129-144.
19
20. Hood TW, Siegfried J, Wieser HG. The role of stereotactic amygdalotomy in the treatment of temporal lobe epilepsy associated with behavioral disorders. Appl Neurophysiol 1983;46:19-25.
20
21. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218-1221.
21
22. Hester ME, Murtha MJ, Song S, Rao M, Miranda CJ, Meyer K, Tian J, Boulting G, Schaffer DV, Zhu MX, Pfaff SL, Gage FH, Kaspar BK. Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes. Mol Ther 2011;19:1905-1912.
22
23. Qu Q, Li D, Louis KR, Li X, Yang H, Sun Q, Crandall SR, Tsang S, Zhou J, Cox CL, Cheng J, Wang F. High-efficiency motor neuron differentiation from human pluripotent stem cells and the function of Islet-1. Nat Commun 2014;5:3462-3449.
23
24. Graebenitz S, Kedo O, Speckmann EJ, Gorji A, Panneck H, Hans V, Palomero-Gallagher N, Schleicher A, Zilles K, Pape HC. Interictal-like network activity and receptor expression in the epileptic human lateral amygdala. Brain 2011;134:2929-2947.
24
25. Mori H, Ninomiya K, Kino-oka M, Shofuda T, Islam MO, Yamasaki M, Okano H, Taya M, Kanemura Y. Effect of neurosphere size on the growth rate of human neural stem/progenitor cells. J Neurosci Res 2006;84:1682-1691.
25
26. Muhr J, Graziano E, Wilson S, Jessell TM, Edlund T. Convergent inductive signals specify midbrain, hindbrain, and spinal cord identity in gastrula stage chick embryos. Neuron 1999;23:689-702.
26
27. Faravelli I, Bucchia M, Rinchetti P, Nizzardo M, Simone C, Frattini E, Corti S. Motor neuron derivation from human embryonic and induced pluripotent stem cells: experimental approaches and clinical perspectives. Stem Cell Res Ther 2014;5:1-13.
27
28. Lamas NJ, Johnson-Kerner B, Roybon L, Kim YA, Garcia-Diaz A, Wichterle H, Henderson CE. Neurotrophic requirements of human motor neurons defined using amplified and purified stem cell-derived cultures. PLoS One 2014;9:e110324.
28
29. Sahab Negah S, Khaksar Z, Aligholi H, Mohammad Sadeghi S, Modarres Mousavi SM, Kazemi H, Jahanbazi Jahan-Abad A, Gorji A. Enhancement of Neural Stem Cell Survival, Proliferation, Migration, and Differentiation in a Novel Self-Assembly Peptide Nanofibber Scaffold. Mol Neurobiol 2017;54:8050-8062.
29
30. Park D, Xiang AP, Mao FF, Zhang L, Di CG, Liu XM, Shao Y, Ma BF, Lee JH, Ha KS, Walton N, Lahn BT. Nestin is required for the proper self-renewal of neural stem cells. Stem Cells 2010;28:2162-2171.
30
31. Pevny LH, Nicolis SK. Sox2 roles in neural stem cells. Int J Biochem Cell Biol 2010;42:421-424.
31
32. Doetsch F, Caillé I, Lim DA, García-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999;97:703-716.
32
33. Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic stem cells into motor neurons. Cell 2002;110:385-397.
33
34. Jaiswal MK. Therapeutic opportunities and challenges of induced pluripotent stem cells-derived motor neurons for treatment of amyotrophic lateral sclerosis and motor neuron disease. Neural Regen Res 2017;12:723-736.
34
35. Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, Resnick T, Benbadis SR. The consequences of refractory epilepsy and its treatment. Epilepsy Behav 2014;37:59-70.
35
36. Thodeson DM, Brulet R, Hsieh J. Neural stem cells and epilepsy: functional roles and disease-in-a-dish models. Cell Tissue Res 2018;371:47-54.
36
37. Rao G, Mashkouri S, Aum D, Marcet P, Borlongan CV. Contemplating stem cell therapy for epilepsy-induced neuropsychiatric symptoms. Neuropsychiatr Dis Treat 2017;13:585-596.
37
38. Aligholi H, Hassanzadeh G, Azari H, Rezayat SM, Mehr SE, Akbari M, Attari F, Khaksarian M, Gorji A. A new and safe method for stereotactically harvesting neural stem/progenitor cells from the adult rat subventricular zone. J Neurosci Methods 2014;225:81-89.
38
39. Soliman MA, Aboharb F, Zeltner N, Studer L. Pluripotent stem cells in neuropsychiatric disorders. Mol Psychiatry 2017;22:1241-1249.
39
40. Jahanbazi Jahan-Abad A, Sahab Negah S, Hosseini Ravandi H, Ghasemi S, Borhani-Haghighi M, Stummer W, Gorji A, Khaleghi Ghadiri M. Human neural stem/progenitor cells derived from epileptic human brain in a self-assembling peptide nanoscaffold improve traumatic brain injury in rats. Mol Neurobiol [Epub ahead of print] doi: 10.1007/s12035-018-1050-1058.
40
ORIGINAL_ARTICLE
Silencing of rhomboid domain containing 1 to inhibit the metastasis of human breast cancer cells in vitro
Objective(s): A growing body of evidence indicates that rhomboid domain containing 1 (RHBDD1) plays an important role in a variety of physiological and pathological processes, including tumorigenesis. We aimed to determine the function of RHBDD1 in breast cancer cells. Materials and Methods: In this study, we used the Oncomine™ database to determine the expression patterns of RHBDD1 in normal and breast cancer tissues. We performed lentiviral transfection of RHBDD1-specific small interfering RNA into the breast cancer cell lines ZR-75-30 and MDA-MB-231 in order to investigate the effects of RHBDD1 deficiency on breast cancer metastasis. Results: We found that knockdown of RHBDD1 inhibited breast cancer cell migration and invasion in vitro. Moreover, knockdown of RHBDD1 promoted epithelial–mesenchymal transition (EMT) by suppressing the expression of MPP2, MPP9, fibronectin 1, vimentin, SRY-box 2, zinc finger E-box binding homeobox 1, and snail family transcriptional repressor 1, and promoting the expression of cadherin 1. Additionally, knockdown of RHBDD1 inhibited the protein expression and phosphorylation of Akt.Conclusion: Our data indicate that RHBDD1 overexpression may promote breast cancer metastasis via the regulation of EMT, suggesting that RHBDD1 may be an important regulator of breast cancer metastasis.
https://ijbms.mums.ac.ir/article_11549_e4fa6d97b814cb26189ba482a298b866.pdf
2018-11-01
1161
1166
10.22038/ijbms.2018.29788.7191
Breast neoplasms
Lentivirus
Neoplasm metastasis
Rhomboid domain containing 1
RNA
Small interfering
Chunjun
Huang
15258287767@139.com
1
Thyroid Breast Surgery, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, 315000, China
LEAD_AUTHOR
Xiaochun
Ji
2955095788@qq.com
2
Thyroid Breast Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, 315000, China
AUTHOR
Yinyin
Peng
pengyingyingv@163.com
3
Thyroid Breast Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, 315000, China
AUTHOR
Minghua
Wu
minhua@vip.sina.com
4
Thyroid Breast Surgery, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, 315000, China
AUTHOR
Weizhu
Wu
1144184462@qq.com
5
Thyroid Breast Surgery, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, 315000, China
AUTHOR
Yong
Luo
13616884736@163.com
6
Thyroid Breast Surgery, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, 315000, China
AUTHOR
Gaoxiang
Cheng
xtkxcgx@126.com
7
Thyroid Breast Surgery, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, 315000, China
AUTHOR
Ye
Zhu
drzhuye@163.com
8
Thyroid Breast Surgery, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, 315000, China
AUTHOR
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67:7-30.
1
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65:87-108.
2
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66:115-132.
3
4. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127:679-695.
4
5. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12:895-904.
5
6. Urban S, Lee JR, Freeman M. Drosophila rhomboid-1 defines a family of putative intramembrane serine proteases. Cell 2001; 107:173-182.
6
7. Urban S. Rhomboid proteins: conserved membrane proteases with divergent biological functions. Genes Dev 2006; 20:3054-3068.
7
8. Etheridge SL, Brooke MA, Kelsell DP, Blaydon DC. Rhomboid proteins: a role in keratinocyte proliferation and cancer. Cell Tissue Res 2013; 351:301-307.
8
9. Wasserman JD, Urban S, Freeman M. A family of rhomboid-like genes: Drosophila rhomboid-1 and roughoid/rhomboid-3 cooperate to activate EGF receptor signaling. Genes Dev 2000; 14:1651-1663.
9
10. McQuibban GA, Saurya S, Freeman M. Mitochondrial membrane remodelling regulated by a conserved rhomboid protease. Nature 2003; 423:537-541.
10
11. Abba MC, Lacunza E, Nunez MI, Colussi A, Isla-Larrain M, Segal-Eiras A, et al. Rhomboid domain containing 2 (RHBDD2): a novel cancer-related gene over-expressed in breast cancer. Biochim Biophys Acta 2009; 1792:988-997.
11
12. Zou H, Thomas SM, Yan ZW, Grandis JR, Vogt A, Li LY. Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB J 2009; 23:425-432.
12
13. Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY, et al. Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol Cancer Ther 2008; 7:1355-1364.
13
14. Lacunza E, Canzoneri R, Rabassa ME, Zwenger A, Segal-Eiras A, Croce MV, et al. RHBDD2: a 5-fluorouracil responsive gene overexpressed in the advanced stages of colorectal cancer. Tumour Biol 2012; 33:2393-2399.
14
15. Wang Y, Guan X, Fok KL, Li S, Zhang X, Miao S, et al. A novel member of the Rhomboid family, RHBDD1, regulates BIK-mediated apoptosis. Cell Mol Life Sci 2008; 65:3822-3829.
15
16. Wei X, Lv T, Chen D, Guan J. Lentiviral vector mediated delivery of RHBDD1 shRNA down regulated the proliferation of human glioblastoma cells. Technol Cancer Res Treat 2014; 13:87-93.
16
17. Song W, Liu W, Zhao H, Li S, Guan X, Ying J, et al. Rhomboid domain containing 1 promotes colorectal cancer growth through activation of the EGFR signalling pathway. Nat Commun 2015; 6:8022.
17
18. Liu XN, Tang ZH, Zhang Y, Pan QC, Chen XH, Yu YS, et al. Lentivirus-mediated silencing of rhomboid domain containing 1 suppresses tumor growth and induces apoptosis in hepatoma HepG2 cells. Asian Pac J Cancer Prev 2013; 14:5-9.
18
19. Lin YN, Gui FM, Shen H, Wang F, Cao Z, Li QH, et al. [Expression of RHBDD1 gene in patients with chronic myeloid leukemia and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2013; 21:12-15.
19
20. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6:1-6.
20
21. Han J, Bai J, Yang Y, Yin H, Gao W, Lu A, et al. Lentivirus-mediated knockdown of rhomboid domain containing 1 inhibits colorectal cancer cell growth. Mol Med Rep 2015; 12:377-381.
21
22. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009; 11:R7.
22
23. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557-563.
23
24. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14:518-527.
24
25. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346-352.
25
26. Ren X, Song W, Liu W, Guan X, Miao F, Miao S, et al. Rhomboid domain containing 1 inhibits cell apoptosis by upregulating AP-1 activity and its downstream target Bcl-3. FEBS Lett 2013; 587:1793-1798.
26
27. Kong D, Li Y, Wang Z, Sarkar FH. Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel) 2011; 3:716-729.
27
28. Ran J, Lin DL, Wu RF, Chen QH, Huang HP, Qiu NX, et al. ZEB1 promotes epithelial-mesenchymal transition in cervical cancer metastasis. Fertil Steril 2015; 103:1606-1614 e1601-1602.
28
29. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15:178-196.
29
30. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014; 16:488-494.
30
31. Xu H, Xiao Q, Fan Y, Xiang T, Li C, Li C, et al. Epigenetic silencing of ADAMTS18 promotes cell migration and invasion of breast cancer through AKT and NF-kappaB signaling. Cancer Med 2017; 6:1399-1408.
31
32. Cui H, Yuan J, Du X, Wang M, Yue L, Liu J. Ethyl gallate suppresses proliferation and invasion in human breast cancer cells via Akt-NF-kappaB signaling. Oncol Rep 2015; 33:1284-1290.
32
33. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3’ kinase/AKT pathways. Oncogene 2005; 24:7443-7454.
33
34. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007; 26:7445-7456.
34
35. Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 2002; 277:3863-3869.
35
36. Saegusa M, Hashimura M, Kuwata T, Okayasu I. Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am J Pathol 2009; 174:2107-2115.
36
ORIGINAL_ARTICLE
Combination of metformin and phenformin synergistically inhibits proliferation and hTERT expression in human breast cancer cells
Objective(s): Breast cancer remains a global challenge, and further chemopreventive therapies are still immediately required. Emerging evidence has revealed the potent anti-cancer effects of biguanides, Metformin (MET) and phenformin (PHE). Thus, to explore an efficient chemopreventive strategy for breast cancer, the antiproliferative effects of the combination of MET and PHE against breast cancer cells were assessed. Materials and Methods: Cytotoxicity of the drugs individually and in combination against T47D and MDA-MB-231 breast cancer cells were assessed using MTT assay and the median-effect method was used to analyze the precise nature of the interaction between MET and PHE. Besides, the expression levels of hTERT after 48 hr drug exposure were determined using qRT-PCR. Results: Based on the cytotoxicity assay, both MET and PHE further inhibited the growth of MDA-MB-231 cells compared with T47D cells. It was found that MET+PHE reduced the IC50s of MET and PHE in both cells drastically more than the single treatments in a synergistic manner. Importantly, MET+PHE showed higher antiproliferative effect with smaller IC50 values against MDA-MB-231 cells than against T47D cells. Real-time PCR results revealed that hTERT expression was significantly reduced in both breast cancer cell lines treated with MET+PHE than the single treatments. In comparison between two types of breast cancer cells, it was detected that MET+PHE could further decline hTERT expression in MDA-MB-231cells than in T47D cells (P<0.001).Conclusion: It is speculated that the combination of MET and PHE may be a promising and convenient approach to improve the efficiency of breast cancer treatment.speculated that the combination of MET and PHE may be a promising and convenient approach to improve the efficiency of breast cancer treatment. It is speculated that the combination of MET and PHE may be a promising and convenient approach to improve the efficiency of breast cancer treatment.
https://ijbms.mums.ac.ir/article_11432_cc0db53afe68f239a8a8cca027b1de07.pdf
2018-11-01
1167
1173
10.22038/ijbms.2018.30460.7345
Breast Cancer
Combination therapy
Metformin
Phenformin
Synergistic effects
Davoud
Jafari-Gharabaghlou
jafari.soba@gmail.com
1
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Younes
Pilehvar-Soltanahmadi
ypilehvar@tbzmed.ac.ir
2
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Mehdi
Dadashpour
dadashpourm@tbzmed.ac.ir
3
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Ali
Mota
mota.biomed@gmail.com
4
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Soheila
Vafajouy-Jamshidi
soheila.vafajou@gmail.com
5
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Leila
Faramarzi
faramarzi.l1370@gmail.com
6
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Sara
Rasouli
rasoulisara12@gmail.com
7
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Nosratollah
Zarghami
zarghami@tbzmed.ac.ir
8
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
LEAD_AUTHOR
1. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram‐Baptiste D, Saslow D, et al. Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2017; 67:100-121.
1
2. Rami A, Zarghami N. Comparison of inhibitory effect of curcumin nanoparticles and free curcumin in human telomerase reverse transcriptase gene expression in breast cancer. Adv Pharm Bull 2013; 3:127.
2
3. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75-89.
3
4. Anari E, Akbarzadeh A, Zarghami N. Chrysin-loaded PLGA-PEG nanoparticles designed for enhanced effect on the breast cancer cell line. Artif Cells Nanomed Biotechnol 2016; 44:1410-1416.
4
5. Orecchioni S, Reggiani F, Talarico G, Mancuso P, Calleri A, Gregato G, et al. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int J Cancer 2015; 136:E534-E544.
5
6. Farajzadeh R, Pilehvar-Soltanahmadi Y, Dadashpour M, Javidfar S, Lotfi-Attari J, Sadeghzadeh H, et al. Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells. Artif Cells Nanomed Biotechnol 2018:46:917-925.
6
7. Maasomi ZJ, Soltanahmadi YP, Dadashpour M, Alipour S, Abolhasani S, Zarghami N. Synergistic anticancer effects of silibinin and chrysin in T47D breast cancer cells. Asian Pac J Cancer Prev 2017; 18:1283.
7
8. Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget 2017; 8: 38022-38043.
8
9. Lotfi-Attari J, Pilehvar-Soltanahmadi Y, Dadashpour M, Alipour S, Farajzadeh R, Javidfar S, et al. Co-delivery of curcumin and chrysin by polymeric nanoparticles inhibit synergistically growth and hTERT gene expression in human colorectal cancer cells. Nutr Cancer 2017; 69:1290-1299.
9
10. Javidfar S, Pilehvar-Soltanahmadi Y, Farajzadeh R, Lotfi-Attari J, Shafiei-Irannejad V, Hashemi M, et al. The inhibitory effects of nano-encapsulated metformin on growth and hTERT expression in breast cancer cells. J Drug Deliv Sci Technol 2018; 43: 19-26.
10
11. Zhang H-H, Guo X-L. Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemother Pharmacol 2016; 78:13-26.
11
12. Liu Z, Ren L, Liu C, Xia T, Zha X, Wang S. Phenformin induces cell cycle change, apoptosis, and mesenchymal-epithelial transition and regulates the AMPK/mTOR/p70s6k and MAPK/ERK pathways in breast cancer cells. PloS one 2015; 10:e0131207.
12
13. Alibakhshi A, Ranjbari J, Pilehvar-Soltanahmadi Y, Nasiri M, Mollazade M, Zarghami N. An update on phytochemicals in molecular target therapy of cancer: potential inhibitory effect on telomerase activity. Curr Med Chem Anticancer Agents 2016; 23:2380-2393.
13
14. Amirsaadat S, Pilehvar-Soltanahmadi Y, Zarghami F, Alipour S, Ebrahimnezhad Z, Zarghami N. Silibinin-loaded magnetic nanoparticles inhibit hTERT gene expression and proliferation of lung cancer cells. Artif Cells Nanomed Biotechnol 2017; 45:1649-1656.
14
15. Pirmoradi S, Fathi E, Farahzadi R, Pilehvar-Soltanahmadi Y, Zarghami N. Curcumin affects adipose tissue-derived mesenchymal stem cell aging through TERT gene expression. Drug Res (Stuttg) 2018; 68:213-221.
15
16. Sadeghzadeh H, Pilehvar-Soltanahmadi Y, Akbarzadeh A, Dariushnejad H, Sanjarian F, Zarghami N. The effects of nanoencapsulated curcumin-Fe3O4 on proliferation and hTERT gene expression in lung cancer cells. Anticancer Agents Med Chem 2017; 17:1363-1373.
16
17. Wang L, Soria J-C, Kemp BL, Liu DD, Mao L, Khuri FR. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res 2002; 8:2883-2889.
17
18. Tavakoli F, Jahanban-Esfahlan R, Seidi K, Jabbari M, Behzadi R, Pilehvar-Soltanahmadi Y, et al. Effects of nano-encapsulated curcumin-chrysin on telomerase, MMPs and TIMPs gene expression in mouse B16F10 melanoma tumour model. Artif Cells Nanomed Biotechnol 2018:1-12.
18
19. Rasouli S, Zarghami N. Synergistic Growth Inhibitory Effects of Chrysin and Metformin Combination on Breast Cancer Cells through hTERT and Cyclin D1 Suppression. Asian Pac J Cancer Prev 2018; 19:977-982.
19
20. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell cycle 2009; 8:909-915.
20
21. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin–dependent translation initiation in breast cancer cells. Cancer Res 2007; 67:10804-10812.
21
22. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase–dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66:10269-10273.
22
23. McGuinness ME, Talbert RL. Phenformin-induced lactic acidosis: a forgotten adverse drug reaction. Ann Pharmacother 1993; 27:1183-1187.
23
24. Zhou J, Huang W, Tao R, Ibaragi S, Lan F, Ido Y, et al. Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene 2009; 28:1993.
24
25. Storozhuk Y, Hopmans S, Sanli T, Barron C, Tsiani E, Cutz J, et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. B Br J Cancer 2013; 108:2021-2032.
25
26. Li B, Takeda T, Tsuiji K, Kondo A, Kitamura M, Wong TF, et al. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway. Gynecol Endocrinol 2013; 29:87-90.
26
27. Zordoky BN, Bark D, Soltys CL, Sung MM, Dyck JR. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta 2014; 1840:1943-1957.
27
28. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011; 71:3196-3201.
28
29. Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer A-C, et al. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 2012; 32:1627-1637.
29
30. Soo JS-S, Ng C-H, Tan SH, Malik RA, Teh Y-C, Tan B-S, et al. Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells. Apoptosis 2015; 20:1373-1387.
30
31. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 2011; 126:355-364.
31
32. Cufí S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, et al. Metformin-induced preferential killing of breast cancer initiating CD44+ CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 2012; 3:395-398.
32
33. Ma J, Guo Y, Chen S, Zhong C, Xue Y, Zhang Y, et al. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC cancer 2014; 14:172-183.
33
34. Jang SY, Kim A, Kim JK, Kim C, Cho Y-H, Kim J-H, et al. Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells. Anticancer Res 2014; 34:4127-4134.
34
35. Rocha GZ, Dias MM, Ropelle ER, Osório-Costa F, Rossato FA, Vercesi AE, et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 2011; 17:3993-4005.
35
36. Miskimins WK, Ahn HJ, Kim JY, Ryu S, Jung Y-S, Choi JY. Synergistic anti-cancer effect of phenformin and oxamate. PloS one 2014; 9:e85576.
36
37. Peng M, Darko KO, Tao T, Huang Y, Su Q, He C, et al. Combination of metformin with chemotherapeutic drugs via different molecular mechanisms. Cancer Treat Rev 2017; 54:24-33.
37
38. Uehara T, Mitsuhashi A, Tsuruoka N, Shozu M. Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro. Oncol Rep 2015; 33:744-750.
38
39. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy. Gynecol Oncol 2010; 116:92-98.
39
40. Montazeri M, Pilehvar-Soltanahmadi Y, Mohaghegh M, Panahi A, Khodi S, Zarghami N, et al. Antiproliferative and apoptotic effect of dendrosomal curcumin nanoformulation in P53 mutant and wide-type cancer cell lines. Anticancer Agents Med Chem 2017; 17:662-673.
40
41. Mohammadian F, Pilehvar-Soltanahmadi Y, Zarghami F, Akbarzadeh A, Zarghami N. Upregulation of miR-9 and Let-7a by nanoencapsulated chrysin in gastric cancer cells. Artif Cells Nanomed Biotechnol 2017; 45:1201-1206.
41
42. Pilehvar-Soltanahmadi Y, Nouri M, Martino MM, Fattahi A, Alizadeh E, Darabi M, Rahmati-Yamchi M, Zarghami N. Cytoprotection, proliferation and epidermal differentiation of adipose tissue-derived stem cells on emu oil based electrospun nanofibrous mat. Exp Cell Res 2017; 357:192-201.
42
ORIGINAL_ARTICLE
Paeoniflorin has anti-inflammation and neurogenesis functions through nicotinic acetylcholine receptors in cerebral ischemia-reperfusion injury rats
Objective(s): Paeoniflorin (PF) has anti-oxidation, anti-inflammation, anti-apoptosis, and neuroprotection pharmacological effects against ischemic injury. The aim of the present study was to investigate the neuroprotection mechanisms of PF in cerebral ischemia-reperfusion injury rats.Materials and Methods: We established an animal model of cerebral infarct by occlusion of the middle cerebral artery for 15 min, followed by reperfusion, and PF was administered 24 hr later (20 mg/kg, intraperitoneally for 6 days) after reperfusionResults: Treatment with PF reduced the neurological deficit score, improved motor function, decreased cell counts of nicotinic acetylcholine receptor (nAChR) α4β2 immunoreactive cells, and increased cell counts of nAChR α7. Furthermore, PF administration suppressed neuronal apoptosis and promoted neurogenesis.Conclusion: PF rescued neurological deficit and underlying mechanisms were inhibition of neurological apoptosis and inflammation by nAChRs.
https://ijbms.mums.ac.ir/article_11550_88d2801f544e912ce7bf5b229a388c53.pdf
2018-11-01
1174
1178
10.22038/ijbms.2018.30371.7322
Apoptosis
Inflammation
Neurogenesis
Nicotinic acetylcholine receptor
Paeoniflorin
Stroke
Cheng-Hang
Ko
navikch@gmail.com
1
Department of Chinese Medicine, China Medical University Hospital, Taichung 40447, Taiwan
AUTHOR
Chun-Ping
Huang
hcpnttw@gmail.com
2
Chinese Medicine Research Center, China Medical University, Taichung 40402, Taiwan
AUTHOR
Yi-Wen
Lin
yiwenlin@mail.cmu.edu.tw
3
Chinese Medicine Research Center, China Medical University, Taichung 40402, Taiwan
AUTHOR
Ching-Liang
Hsieh
clhsieh@mail.cmuh.org.tw
4
Department of Chinese Medicine, China Medical University Hospital, Taichung 40447, Taiwan
LEAD_AUTHOR
1. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007; 184:53-68.
1
2. Wu PF, Zhang Z, Wang F, Chen JG. Natural compounds from traditional medicinal herbs in the treatment of cerebral ischemia/reperfusion injury. Acta Pharmacol Sin 2010; 31:1523-1531.
2
3. Xiao L, Wang YZ, Liu J, Luo XT, Ye Y, Zhu XZ. Effects of paeoniflorin on the cerebral infarction, behavioral and cognitive impairments at the chronic stage of transient middle cerebral artery occlusion in rats. Life Sci 2005; 78:413-420.
3
4. Tang NY, Liu CH, Hsieh CT, Hsieh CL. The anti-inflammatory effect of paeoniflorin on cerebral infarction induced by ischemia-reperfusion injury in Sprague-Dawley rats. Am J Chin Med 2010; 38:51-64.
4
5. Liu DZ, Xie KQ, Ji XQ, Ye Y, Jiang CL, Zhu XZ. Neuroprotective effect of paeoniflorin on cerebral ischemic rat by activating adenosine A1 receptor in a manner different from its classical agonists. Br J Pharmacol 2005; 146:604-611.
5
6. Chen DM, Xiao L, Cai X, Zeng R, Zhu XZ. Involvement of multitargets in paeoniflorin-induced preconditioning. J Pharmacol Exp Ther 2006; 319:165-180.
6
7. Picciotto MR, Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Front Biosci 2008; 13:492-504.
7
8. Belluardo N, Mudo G, Blum M, Fuxe K. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res 2000; 113:21-34.
8
9. de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 2007; 151:915-929.
9
10. Mukhin AG, Gundisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS, et al. 5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 2000; 57:642-649.
10
11. Martin A, Szczupak B, Gomez-Vallejo V, Domercq M, Cano A, Padro D, et al. In vivo PET imaging of the alpha4beta2 nicotinic acetylcholine receptor as a marker for brain inflammation after cerebral ischemia. J Neurosci 2015; 35:5998-6009.
11
12. Yakel JL. Nicotinic ACh receptors in the hippocampal circuit; functional expression and role in synaptic plasticity. J Physiol 2014; 592:4147-4153.
12
13. Narla S, Klejbor I, Birkaya B, Lee YW, Morys J, Stachowiak EK, et al. Alpha7 nicotinic receptor agonist reactivates neurogenesis in adult brain. Biochem Pharmacol 2013; 86:1099-1104.
13
14. Kuo CT, Lin YW, Tang NY, Cheng CY, Hsieh CL. Electric stimulation of the ears ameliorated learning and memory impairment in rats with cerebral ischemia-reperfusion injury. Sci Rep 2016; 6:20381.
14
15. Zaleska MM, Mercado ML, Chavez J, Feuerstein GZ, Pangalos MN, Wood A. The development of stroke therapeutics: promising mechanisms and translational challenges. Neuropharmacology 2009; 56:329-341.
15
16. Neumann S, Shields NJ, Balle T, Chebib M, Clarkson AN. Innate Immunity and Inflammation Post-Stroke: An alpha7-Nicotinic Agonist Perspective. Int J Mol Sci 2015; 16:29029-29046.
16
17. Tracey KJ. The inflammatory reflex. Nature 2002; 420:853-859.
17
18. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 2005; 6:775-786.
18
19. Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009; 9:418-428.
19
20. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405:458-462.
20
21. Cai PY, Bodhit A, Derequito R, Ansari S, Abukhalil F, Thenkabail S, et al. Vagus nerve stimulation in ischemic stroke: old wine in a new bottle. Front Neurol 2014; 5:107.
21
22. Krafft PR, Altay O, Rolland WB, Duris K, Lekic T, Tang J, et al. Alpha7 nicotinic acetylcholine receptor agonism confers neuroprotection through GSK-3beta inhibition in a mouse model of intracerebral hemorrhage. Stroke 2012; 43:844-850.
22
23. Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, et al. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006; 116:2208-2217.
23
ORIGINAL_ARTICLE
Iranian crack induces hepatic injury through mitogen-activated protein kinase pathway in the liver of Wistar rat
Objective(s): Iranian crack (IC) is a heroin-based substance manifesting various pathologic side effects. Herein, we aimed to investigate the mechanism of IC-induced liver injuries in Wistar rats. Materials and Methods: Twenty male Wistar rats were randomly divided into two groups: control, and IC (0.9 mg/kg/day/IP, for 30 days). Mitochondrial reactive oxygen species (ROS) production was measured by DCF fluorescence staining. The expression of tumor necrosis factor-alpha (TNF-α), interleukin 1β (IL-1β), and phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK) and c-Jun N-terminal kinase (c-JNK) were assessed by immunoblotting assay. The intensity of collagen fiber in the liver was also determined by Trichrome-Masson staining. Furthermore, serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) activities were measured using colorimetric methods. Results: Our results showed that ROS production, p38 MAPK, c-JNK phosphorylation levels, and expression of TNF-α and IL-1β were significantly elevated in the liver tissue of IC group as compared to the control group. Moreover, collagen fiber and ALT activity were increased in the liver tissue of IC group compared to the control group. However, there was no statistically significant difference in the levels of ALP between two groups. In addition, there was a positive correlation between the intensity of collagen fiber and the ALT activity, and the levels of TNF-α and IL-1β and liver enzymes activities including ALP, ALT, and AST.Conclusion: Our findings revealed that IC-induced liver cells injury is partially mediated by MAPK stress kinases. Therefore, regular liver examination in substance abuse is strongly recommended.
https://ijbms.mums.ac.ir/article_11552_2c02d44b03bb9936d3daadb3de27a5fd.pdf
2018-11-01
1179
1185
10.22038/ijbms.2018.23543.5930
Cytokines
c-JNK
Iranian Crack
Liver fibrosis
p38 MAPK
Transaminase
Aliasghar
Parvaresh Anbar
aliparvaresh715@gmail.com
1
Higher Academic Education Institute of Rab-e Rashid, Tabriz, Iran
AUTHOR
Tayyebeh
Piran
tayyebeh.piran@gmail.com
2
Higher Academic Education Institute of Rab-e Rashid, Tabriz, Iran
AUTHOR
Mehrdad
Farhadi
mehrdad_farhadi62@yahoo.com
3
Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Pouran
karimi
pouran.karimi@yahoo.com
4
Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
LEAD_AUTHOR
1. Chan Y-Y, Yang S-N, Lin J-C, Chang J-L, Lin J-G, Lo W-Y. Inflammatory response in heroin addicts undergoing methadone maintenance treatment. Psychia Res 2015;226:230-234.
1
2. Samarghandian S, Afshari R, Farkhondeh T. Effect of long-term treatment of morphine on enzymes, oxidative stress indices and antioxidant status in male rat liver. Int J Clin Exp Med 2014;7:1449-1453.
2
3. Farhoudian A, Sadeghi M, Moazen B, Fekri M. Component analysis of Iranian crack; a newly abused narcotic substance in Iran. Iran J Pharmaceu Res 2013;13:337-344.
3
4. Amiri M, Khosravi A, Chaman R. Drug abuse pattern and high risk behaviors among addicts in Shahroud county of Semnan province, Northeast Iran in 2009. J Res Health Sci 2010;10:104-109.
4
5. Mohammad KA, Hassan S, Dariush B. Crack in Iran: is it really cocaine? J Addict Res Ther 2013;2011.
5
6. Filimonov P, Sukhenko T, Papantonopulo A, Gavrilova N, Shkurupii V. Level of liver fibrosis and immune status of mice of different age after heroin treatment and long abstinence. Bull Exp Biol Med 2005;140:723-725.
6
7. Smith HS. Opioid Metabolism. Mayo Clin Proc;84:613-624.
7
8. Tsutsui H, Cai X, Hayashi S. Interleukin-1 Family Cytokines in Liver Diseases. Mediators Inflamm 2015;2015.
8
9. Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 2015;12:387-400.
9
10. Bataller R, xF, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.
10
11. Xu R, Zhang Z, Wang F-S. Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol Immunol 2012;9:296-301.
11
12. Yang YM, Seki E. TNFα in Liver Fibrosis. Curr Pathobiol Rep 2015;3:253-261.
12
13. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2016;117:539-548.
13
14. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol 2007;22:S73-S78.
14
15. Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006;21:S84-S87.
15
16. Bekheet SHM. Morphine sulphate induced histopathological and histochemical changes in the rat liver. Tissue Cell 2010;42:266-272.
16
17. Reeves HL, Friedman SL. Activation of hepatic stellate cells-a key issue in liver fibrosis. Front Biosci 2002;7:808-826.
17
18. Schwabe RF, Bradham CA, Uehara T, Hatano E, Bennett BL, Schoonhoven R et al. c‐Jun‐N‐terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology 2003;37:824-832.
18
19. Yamamoto T, Kojima T, Murata M, Takano K-i, Go M, Hatakeyama N et al. p38 MAP-kinase regulates function of gap and tight junctions during regeneration of rat hepatocytes. J Hepatol 2005;42:707-718.
19
20. Lee M. Basic skills in interpreting laboratory data: ASHP; 2009.
20
21. Zhan Y-Y, Wang J-H, Tian X, Feng S-X, Xue L, Tian L-P. Protective effects of seed melon extract on CCl4-induced hepatic fibrosis in mice. J Ethnopharmacol 2016;193:531-537.
21
22. Pacifici R, di Carlo S, Bacosi A, Pichini S, Zuccaro P. Pharmacokinetics and cytokine production in heroin and morphine-treated mice. Int J Immunopharmacol 2000;22:603-614.
22
23. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425-456.
23
24. Sekiyama KD, Yoshiba M, Thomson AW. Circulating proinflammatory cytokines (IL-1β, TNF-α, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. J Clin Exp Immunol 1994;98:71-77.
24
25. Salehpour F, Farajdokht F, Erfani M, Sadigh-Eteghad S, Shotorbani SS, Hamblin MR et al. Transcranial near-infrared photobiomodulation attenuates memory impairment and hippocampal oxidative stress in sleep-deprived mice. Brain Research 2018;1682:36-43.
25
26. Xie R, Zhang H, Wang X-z, Yang X-z, Wu S-n, Wang H-g et al. The protective effect of betulinic acid (BA) diabetic nephropathy on streptozotocin (STZ)-induced diabetic rats. Food Funct 2017;8:299-306.
26
27. Xu Y, Liu W, Fang B, Gao S, Yan J. Artesunate ameliorates hepatic fibrosis induced by bovine serum albumin in rats through regulating matrix metalloproteinases. Eur J Pharmacol 2014;744:1-9.
27
28. Li R, Song J, Wu W, Wu X, Su M. Puerarin exerts the protective effect against chemical induced dysmetabolism in rats. Gene 2016;595:168-174.
28
29. Farajdokht F, Mohaddes G, Karimi-Sales E, Kafshdooz T, Mahmoudi J, Aberoumandi SM et al. Inhibition of PTEN protects PC12 cells against oxygen-glucose deprivation induced cell death through mitoprotection. Brain Res 2018;1692:100-109.
29
30. El Sohafy SM, Metwally AM, Omar AA, Amer ME, Radwan MM, Abdel-Kader MS et al. Cornigerin, a new sesqui-lignan from the hepatoprotective fractions of Cynara cornigera L. Fitoterapia 2016;115:101-105.
30
31. Sadeghi M, Farhoudian A, Vishteh HR, Rahimzadeh S, Fekri M, Movaghar AR et al. A tentative component analysis of Norjizak: A new abused drug in Iran. Pakistan journal of pharmaceutical sciences 2015;28:1631-1636.
31
32. Saleh Gargari S, Fallahian M, Haghighi L, Hosseinnezhad-Yazdi M, Dashti E, Dolan K. Maternal and neonatal complications of substance abuse in Iranian pregnant women. Acta medica Iranica 2012;50:411-416.
32
33. Behnam B, Semnani V, Saghafi N, Ghorbani R, Dianak Shori M, Ghooshchian Choobmasjedi S. Gabapentin effect on pain associated with heroin withdrawal in Iranian crack: a randomized double-blind clinical trial. Iran J Pharmaceu Res 2012;11:979-983.
33
34. Czaja MJ. Induction and regulation of hepatocyte apoptosis by oxidative stress. Antioxid Redox Signal 2002;4:759-767.
34
35. Zhang YT, Zheng QS, Pan J, Zheng RL. Oxidative damage of biomolecules in mouse liver induced by morphine and protected by antioxidants. Basic Clin Pharmacol Toxicol 2004;95:53-58.
35
36. Shuster L. Morphine and Liver Damage. In: Watson RR, editor. Liver Pathology and Alcohol. Totowa, NJ: Humana Press; 1991. p. 593-616.
36
37. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-485.
37
38. Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clin Liver Dis 2017;21:1-20.
38
39. Payabvash S, Beheshtian A, Salmasi AH, Kiumehr S, Ghahremani MH, Tavangar SM et al. Chronic morphine treatment induces oxidant and apoptotic damage in the mice liver. Life Sci 2006;79:972-980.
39
40. Pan J, Zhang Q, Zhang Y, Ouyang Z, Zheng Q, Zheng R. Oxidative stress in heroin administered mice and natural antioxidants protection. Life Sci 2005;77:183-193.
40
41. Moreira S, Stramer B, Evans I, Wood W, Martin P. Prioritization of competing damage and developmental signals by migrating macrophages in the Drosophila embryo. Curr Biol 2010;20:464-470.
41
42. Santabárbara-Ruiz P, López-Santillán M, Martínez-Rodríguez I, Binagui-Casas A, Pérez L, Milán M et al. ROS-induced JNK and p38 signaling is required for unpaired cytokine activation during drosophila regeneration. PLoS Genetics 2015;11:e1005595.
42
43. Jia Y-T, Wei W, Ma B, Xu Y, Liu W-J, Wang Y et al. Activation of p38 MAPK by reactive oxygen species is essential in a rat model of stress-induced gastric mucosal injury. J Immunol 2007;179:7808-7819.
43
44. Liu T, Zhou Y, Ko KS, Yang H. Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases. Mediators Inflamm 2015;2015.
44
45. Jensen LE, Muzio M, Mantovani A, Whitehead AS. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol 2000;164:5277-5286.
45
46. Bieghs V, Trautwein C. The innate immune response during liver inflammation and metabolic disease. Trends Immunol 2013;34:446-452.
46
47. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
47
48. Deng M, Loughran PA, Zhang L, Scott MJ, Billiar TR. Shedding of the tumor necrosis factor (TNF) receptor from the surface of hepatocytes during sepsis limits inflammation through cGMP signaling. Sci Signal 2015;8:ra11-ra11.
48
49. Liedtke C, Luedde T, Sauerbruch T, Scholten D, Streetz K, Tacke F et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair 2013;6:1-25.
49
50. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014;14:181-194.
50
51. Gomez A, Stockert JC, Mosquera RM, Del Castillo P, Tena G, Sancho M. Chronic intoxication by heroin; histopathological effects on seminiferous tubules. Forensic Sci Int 1989;43:97-101.
51
52. de Araújo MST, Gérard F, Chossegros P, Guerret S, Barlet P, Adeleine P et al. Cellular and matrix changes in drug abuser liver sinusoids: a semiquantitative and morphometric ultrastructural study. Virchows Archiv A 1993;422:145-152.
52
53. Ilić G, Kostić-Banović L, Karadžić R, Stojanović J. The electron-microscopic findings on the liver in chronic abuse of heroin. Facta Universitatis Series Igaku To Seibutsugaku 2006;13:6-10.
53
ORIGINAL_ARTICLE
CircRNA_0109291 regulates cell growth and migration in oral squamous cell carcinoma and its clinical significance
Objective(s): Circular RNAs (circRNAs), a new class of non-coding RNAs, have emerged as important regulators during tumorigenesis. However, the functions of circRNAs have not been completely clarified in the progression of cancers. In our study, a novel circRNA hsa_circ_0109291 was investigated in oral squamous cell carcinoma (OSCC) tissues and cell lines. Materials and Methods: The expression profile of circRNAs in OSCC tumor tissues was performed by high-throughput sequencing. The CCK-8 wound healing and apoptosis assay were measured in OSCC cell lines after transfection with si-0109291 or si-NC. Results: We discovered that hsa_circ_0109291 was significantly increased in OSCC tissues and cell lines compared with their corresponding control group. Knockdown of hsa_circ_0109291 inhibited proliferation and migration of OSCC cell lines in vitro. In addition, inhibition of hsa_circ_0109291 dramatically induced apoptosis of OSCC cells. We further found that high hsa_circ_0109291 levels in OSCC patients resulted in a poorer prognosis than in patients with low hsa_circ_0109291 levels. Conclusion: These findings indicated that hsa_circ_0109291 correlated with the progression of OSCC and might be a new therapeutic target for the treatment of OSCC.
https://ijbms.mums.ac.ir/article_11442_340490f89f0e7ec436fa4cd35b493c54.pdf
2018-11-01
1186
1191
10.22038/ijbms.2018.30347.7313
Apoptosis
CircRNA
Hsa_circ_0109291
Oral squamous cell carcinoma
Prognosis
Shao-Bo
Ouyang
bsjvrjvva402514@163.com
1
Department of Oral Prosthodontics, the Affiliated Stomatological Hospital of Nanchang University, Jiangxi Provincial Key Laboratory of Oral Biomedicine, Nanchang 330006, China
AUTHOR
Jun
Wang
xbhifl07895@163.com
2
Department of Oral and Maxillofacial Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, China
AUTHOR
Si-Yu
Zhao
elvbwy668215@163.com
3
Department of Oral Prosthodontics, the Affiliated Stomatological Hospital of Nanchang University, Jiangxi Provincial Key Laboratory of Oral Biomedicine, Nanchang 330006, China
AUTHOR
Xian-Hua
Zhang
rengfan74036@163.com
4
Department of Oral Prosthodontics, the Affiliated Stomatological Hospital of Nanchang University, Jiangxi Provincial Key Laboratory of Oral Biomedicine, Nanchang 330006, China
AUTHOR
Lan
Liao
liao_lan12@outlook.com
5
Department of Oral Prosthodontics, the Affiliated Stomatological Hospital of Nanchang University, Jiangxi Provincial Key Laboratory of Oral Biomedicine, Nanchang 330006, China
LEAD_AUTHOR
1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-236.
1
2. Yang CN, Deng YT, Tang JY, Cheng SJ, Chen ST, Li YJ, et al. MicroRNA-29b regulates migration in oral squamous cell carcinoma and its clinical significance. Oral Oncol 2015; 51:170-177.
2
3. Kademani D. Oral cancer. Mayo Clin Proc 2007; 82:878-887.
3
4. Sun CC, Zhang L, Li G, Li SJ, Chen ZL, Fu YF, et al. The lncRNA PDIA3P interacts with miR-185-5p to modulate oral squamous cell carcinoma progression by targeting cyclin D2. Mol Ther Nucleic Acids 2017; 9:100-110.
4
5. Massano J, Regateiro FS, Januario G, Ferreira A. Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102:67-76.
5
6. Lai YH, Liu H, Chiang WF, Chen TW, Chu LJ, Yu JS, et al. MiR-31-5p-ACOX1 axis enhances tumorigenic fitness in oral squamous cell carcinoma via the promigratory prostaglandin E2. Theranostics 2018; 8:486-504.
6
7. Hashiguchi Y, Kawano S, Goto Y, Yasuda K, Kaneko N, Sakamoto T, et al. Tumor-suppressive roles of DeltaNp63beta-miR-205 axis in epithelial-mesenchymal transition of oral squamous cell carcinoma via targeting ZEB1 and ZEB2. J Cell Physiol 2017.
7
8. Ding L, Ren J, Zhang D, Li Y, Huang X, Hu Q, et al. A novel stromal lncRNA signature reprograms fibroblasts to promote the growth of oral squamous cell carcinoma via LncRNA-CAF/interleukin-33. Carcinogenesis 2018.
8
9. Liang S, Zhang S, Wang P, Yang C, Shang C, Yang J, et al. LncRNA, TUG1 regulates the oral squamous cell carcinoma progression possibly via interacting with Wnt/beta-catenin signaling. Gene 2017; 608:49-57.
9
10. Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol 2015; 12:381-388.
10
11. Hsu MT, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature 1979; 280:339-340.
11
12. Zhou B, Yu JW. A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-beta1. Biochem Biophys Res Commun 2017; 487:769-775.
12
13. Zhao Y, Alexandrov PN, Jaber V, Lukiw WJ. Deficiency in the ubiquitin conjugating enzyme UBE2A in Alzheimer’s disease (AD) is linked to deficits in a natural circular miRNA-7 sponge (circRNA; ciRS-7). Genes (Basel) 2016; 7.
13
14. Qian Y, Lu Y, Rui C, Qian Y, Cai M, Jia R. Potential significance of circular RNA in human placental tissue for patients with preeclampsia. Cell Physiol Biochem 2016; 39:1380-1390.
14
15. Liu Q, Zhang X, Hu X, Dai L, Fu X, Zhang J, et al. Circular RNA related to the chondrocyte ECM regulates MMP13 expression by functioning as a MiR-136 ‘Sponge’ in human cartilage degradation. Sci Rep 2016; 6:22572.
15
16. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013; 495:384-388.
16
17. Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Li P, et al. CircRNA: functions and properties of a novel potential biomarker for cancer. Mol Cancer 2017; 16:94.
17
18. Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun 2016; 7:11215.
18
19. Li F, Zhang L, Li W, Deng J, Zheng J, An M, et al. Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/beta-catenin pathway. Oncotarget 2015; 6:6001-6013.
19
20. Han D, Li J, Wang H, Su X, Hou J, Gu Y, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology 2017; 66:1151-1164.
20
21. Liang HF, Zhang XZ, Liu BG, Jia GT, Li WL. Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271. Am J Cancer Res 2017; 7:1566-1576.
21
22. Zhang J, Liu H, Hou L, Wang G, Zhang R, Huang Y, et al. Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol Cancer 2017; 16:151.
22
23. Zhang XL, Xu LL, Wang F. Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR-138 targets TERT and PD-L1. Cell Biol Int 2017; 41:1056-1064.
23
24. Chen L, Zhang S, Wu J, Cui J, Zhong L, Zeng L, et al. circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family. Oncogene 2017; 36:4551-4561.
24
25. Wang L, Wei Y, Yan Y, Wang H, Yang J, Zheng Z, et al. CircDOCK1 suppresses cell apoptosis via inhibition of miR196a5p by targeting BIRC3 in OSCC. Oncol Rep 2017.
25
26. Li L, Guo J, Chen Y, Chang C, Xu C. Comprehensive CircRNA expression profile and selection of key CircRNAs during priming phase of rat liver regeneration. BMC Genomics 2017; 18:80.
26
27. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013; 495:333-338.
27
28. Fang S, Guo H, Cheng Y, Zhou Z, Zhang W, Han B, et al. circHECTD1 promotes the silica-induced pulmonary endothelial-mesenchymal transition via HECTD1. Cell Death Dis 2018; 9:396.
28
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:402-408.
29
30. Momen-Heravi F, Bala S. Emerging role of non-coding RNA in oral cancer. Cell Signal 2018; 42:134-143.
30
31. Wang L, Wei Y, Yan Y, Wang H, Yang J, Zheng Z, et al. CircDOCK1 suppresses cell apoptosis via inhibition of miR196a5p by targeting BIRC3 in OSCC. Oncol Rep 2018; 39:951-966.
31
32. Kwon YW, Ahn HS, Park JY, Yang HM, Cho HJ, Kim HS. Imprinted gene Zinc finger protein 127 is a novel regulator of master pluripotency transcription factor, Oct4. BMB Rep 2018; 51:242-248.
32
33. Jen J, Wang YC. Zinc finger proteins in cancer progression. J Biomed Sci 2016; 23:53.
33
34. Wang H, Deng X, Zhang J, Ou Z, Mai J, Ding S, et al. Elevated expression of zinc finger protein 703 promotes cell proliferation and metastasis through PI3K/AKT/GSK-3beta signalling in oral squamous cell carcinoma. Cell Physiol Biochem 2017; 44:920-934.
34
35. Jou YJ, Lin CD, Lai CH, Tang CH, Huang SH, Tsai MH, et al. Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages. Clin Chim Acta 2011; 412:1357-1365.
35
36. Yang H, Pan L, Xu C, Zhang Y, Li K, Chen S, et al. Overexpression of tumor suppressor gene ZNF750 inhibits oral squamous cell carcinoma metastasis. Oncol Lett 2017; 14:5591-5596.
36
37. Pang F, Zha R, Zhao Y, Wang Q, Chen D, Zhang Z, et al. MiR-525-3p enhances the migration and invasion of liver cancer cells by downregulating ZNF395. PLoS One 2014; 9:e90867.
37
38. Chen S, Li T, Zhao Q, Xiao B, Guo J. Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer. Clin Chim Acta 2017; 466:167-171.
38
39. Yao JT, Zhao SH, Liu QP, Lv MQ, Zhou DX, Liao ZJ, et al. Over-expression of CircRNA_100876 in non-small cell lung cancer and its prognostic value. Pathol Res Pract 2017; 213:453-456.
39
40. Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z, et al. Hsa_circ_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma. Cancer Biomark 2016; 16:161-169.
40
41. Shang X, Li G, Liu H, Li T, Liu J, Zhao Q, et al. Comprehensive circular RNA profiling reveals that hsa_circ_0005075, a new circular RNA biomarker, is involved in hepatocellular crcinoma development. Medicine (Baltimore) 2016; 95:e3811.
41
42. Fu L, Yao T, Chen Q, Mo X, Hu Y, Guo J. Screening differential circular RNA expression profiles reveals hsa_circ_0004018 is associated with hepatocellular carcinoma. Oncotarget 2017; 8:58405-58416.
42
ORIGINAL_ARTICLE
The effects of crocetin, extracted from saffron, in chemotherapy against the incidence of multiple drug resistance phenotype
Objective(s): Crocetin, one of the main substances of saffron extract, has anti-cancer effects. Drug resistance proteins (e.g. MRP1 and MRP2) are important reasons for the failure of cancer therapy. We intended to investigate the efficacy of crocetin on MRP1 and MRP2 activity in human ovarian cisplatin-resistant carcinoma cell line (A2780-RCIS).Materials and Methods: The cytotoxic effect of crocetin was evaluated by the MTT assay. The efficacy of crocetin on MRP1 and MRP2 expression at mRNA level was studied by real-time RT-PCR. The effect of crocetin on the activity of MRP transporters was determined by drug efflux assay.Results: Crocetin decreased cell proliferation in the A2780 (IC50: 183±7 µM) and A2780-RCIS (IC50: 316±9 µM). Crocetin decreased the expression level of MRP1 (22±2 %) and MRP2 (48±8 %) in A2780-RCIS and inhibited MRP pumps function directly in A2780 (44±1 %) and A2780-RCIS (88±10 %) and indirectly in A2780 (32±2 %) and A2780-RCIS (48±15 %) respectively. Conclusion: Our findings showed that crocetin could quench drug resistance through modulation of MRP transporters in the drug resistant human ovarian cancer cells.
https://ijbms.mums.ac.ir/article_11612_133836ee9eac44219388142450d1cf73.pdf
2018-11-01
1192
1197
10.22038/ijbms.2018.29474.7118
A2780
A2780-RCIS
Crocetin
MRP
Ovarian cancer cell line
Navid
Neyshaburinezhad
navid.pha2@gmail.com
1
Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Maryam
Hashemi
hashemim@mums.ac.ir
2
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mohammad
Ramezani
ramezanim@mums.ac.ir
3
Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Sepideh
Arabzadeh
arabzadehs@mums.ac.ir
4
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Javad
Behravan
behravanj@mums.ac.ir
5
Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Fatemeh
Kalalinia
kalaliniaf@mums.ac.ir
6
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Zare-Shahabadi A, Langroodi HG, Azimi AR, Sahraian MA, Harirchian MH, Baghbanian SM. Neuromyelitis optica and pregnancy. Acta Neurol Belg. 2016;116:431-438.
1
2. Violette PD, Saad F. Chemoprevention of prostate cancer: myths and realities. J Am Board Fam Med. 2012;25:111-119.
2
3. Schuster M, Nechansky A, Kircheis R. Cancer immunotherapy. Biotechnol J. 2006;1:138-147.
3
4. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11:265-283.
4
5. Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev. 2009;109:2989-3011.
5
6. Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol. 1999;128:563-568.
6
7. HemaIswarya S, Doble M. Potential synergism of natural products in the treatment of cancer. Phytother Res. 2006;20:239-249.
7
8. Abe K, Saito H. Effects of saffron extract and its constituent crocin on learning behaviour and long-term potentiation. Phytother Res. 2000;14:149-152.
8
9. Srivastava R, Ahmed H, Dixit RK, Dharamveer, Saraf SA. Crocus sativus L.: A comprehensive review. Pharmacogn Rev. 2010;4:200-208.
9
10. Zarei Jaliani H, Riazi GH, Ghaffari SM, Karima O, Rahmani A. The effect of the crocus sativus L. Carotenoid, crocin, on the polymerization of microtubules, in vitro. Iran J Basic Med Sci. 2013;16:101-107.
10
11. Mahdizadeh S, Karimi G, Behravan J, Arabzadeh S, Lage H, Kalalinia F. Crocin suppresses multidrug resistance in MRP overexpressing ovarian cancer cell line. Daru. 2016;24:17.
11
12. Giaccio M. Crocetin from saffron: an active component of an ancient spice. Crit Rev Food Sci Nutr. 2004;44:155-172.
12
13. Gutheil WG, Reed G, Ray A, Anant S, Dhar A. Crocetin: an agent derived from saffron for prevention and therapy for cancer. Curr Pharm Biotechnol. 2012;13:173-179.
13
14. Kim SH, Lee JM, Kim SC, Park CB, Lee PC. Proposed cytotoxic mechanisms of the saffron carotenoids crocin and crocetin on cancer cell lines. Biochem Cell Biol. 2014;92:105-111.
14
15. Timm M, Saaby L, Moesby L, Hansen EW. Considerations regarding use of solvents in in vitro cell based assays. Cytotechnology. 2013;65:887-894.
15
16. Anger GJ, Cressman AM, Piquette-Miller M. Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes. PLoS One. 2012;7:e35027.
16
17. Gotze S, Feldhaus V, Traska T, Wolter M, Reifenberger G, Tannapfel A, et al. ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer. 2009;9:447.
17
18. Yamaguchi S, Zhao YL, Nadai M, Yoshizumi H, Cen X, Torita S, et al. Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006;50:80-87.
18
19. Janneh O, Jones E, Chandler B, Owen A, Khoo SH. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother. 2007;60:987-993.
19
20. Huang M, Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett. 1999;135:97-105.
20
21. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc). 2000;65:95-106.
21
22. Abdullaev FI. Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Exp Biol Med (Maywood). 2002;227:20-25.
22
23. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999;55:929-937.
23
24. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 1997;57:5475-5479.
24
25. Gyemant N, Tanaka M, Molnar P, Deli J, Mandoky L, Molnar J. Reversal of multidrug resistance of cancer cells in vitro: modification of drug resistance by selected carotenoids. Anticancer Res. 2006;26:367-374.
25
26. Shen J, Cross ST, Tang-Liu DD, Welty DF. Evaluation of an immortalized retinal endothelial cell line as an in vitro model for drug transport studies across the blood-retinal barrier. Pharm Res. 2003;20:1357-1363.
26
27. Eid SY, El-Readi MZ, Wink M. Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012;19:977-987.
27
28. Zhong YJ, Shi F, Zheng XL, Wang Q, Yang L, Sun H, et al. Crocetin induces cytotoxicity and enhances vincristine-induced cancer cell death via p53-dependent and -independent mechanisms. Acta Pharmacol Sin. 2011;32:1529-1536.
28